Clinical trial NCT00262600: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Official title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Atrial Fibrillation
Stroke
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
Collaborators: name: Population Health Research Institute
name: Uppsala University
First posted: 2005-12-07
Enrollment: 18113
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.


Eligibility criteria: Inclusion criteria Patients with non-valvular atrial fibrillation (AF), at moderate to high risk of stroke, or systemic embolism with at least one additional risk factor (i.e. previous ischemic stroke, TIA, or systemic embolism, left ventricular dysfunction, age \>=75 years, age \>=65 with either diabetes mellitus, history of coronary artery disease or hypertension)

Exclusion criteria

1. Prosthetic heart valves requiring anticoagulation per se, or hemodynamically relevant valve disease that is expected to require surgical intervention during the course of the study
2. Severe, disabling stroke within the previous 6 months, or any stroke within the previous 14 days
3. Conditions associated with an increased risk of bleeding
4. Contraindication to warfarin treatment
5. Reversible causes of atrial fibrillation (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism).
6. Plan to perform a pulmonary vein ablation or surgery for cure of the AF
7. Severe renal impairment (estimated creatinine clearance \<=30 mL/min)
8. Active infective endocarditis
9. Active liver disease
10. Women who are pregnant, lactating, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study
11. Anaemia (haemoglobin \<100g/L) or thrombocytopenia (platelet count \<100 x 109/L)
12. Patients who have developed transaminase elevations upon exposure to ximelagatran
13. Patients who have received an investigational drug in the past 30 days or are participating in another drug study
14. Patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration, has a life expectancy less than the expected duration of the trial due to concomitant disease, or has any condition which in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse)
15. Any known hypersensitivity to galactose if the warfarin used contains galactose.

Primary outcomes:
measure: Yearly Event Rate for Composite Endpoint of Stroke/SEE
timeFrame: 36 months
Secondary outcomes:
measure: Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death
timeFrame: 36 months
measure: Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death
timeFrame: 36 months
measure: Bleeding Events (Major and Minor)
timeFrame: 36 months
measure: Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)
timeFrame: 36 months
measure: Abnormal Liver Function Test
timeFrame: 36 months
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: 1160.26.0009 Boehringer Ingelheim Investigational Site
state: Alabama
city: Birmingham
country: United States
facility: 1160.26.0046 Boehringer Ingelheim Investigational Site
state: Alabama
city: Birmingham
country: United States
facility: 1160.26.0057 Boehringer Ingelheim Investigational Site
state: Alabama
city: Birmingham
country: United States
facility: 1160.26.0211 Boehringer Ingelheim Investigational Site
state: Alabama
city: Huntsville
country: United States
facility: 1160.26.0206 Boehringer Ingelheim Investigational Site
state: Alabama
city: Mobile
country: United States
facility: 1160.26.0115 Boehringer Ingelheim Investigational Site
state: Alabama
city: Lake Havasu City
country: United States
facility: 1160.26.0104 Boehringer Ingelheim Investigational Site
state: Arizona
city: Peoria
country: United States
facility: 1160.26.0304 Boehringer Ingelheim Investigational Site
state: Arizona
city: Tucson
country: United States
facility: 1160.26.0185 Boehringer Ingelheim Investigational Site
state: Arizona
city: Tucson
country: United States
facility: 1160.26.0305 Boehringer Ingelheim Investigational Site
state: Arizona
city: Hot Springs
country: United States
facility: 1160.26.0038 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Jonesboro
country: United States
facility: 1160.26.0302 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Little Rock
country: United States
facility: 1160.26.0121 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Little Rock
country: United States
facility: 1160.26.0191 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Little Rock
country: United States
facility: 1160.26.0204 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Little Rock
country: United States
facility: 1160.26.0213 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Little Rock
country: United States
facility: 1160.26.0455 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Anaheim
country: United States
facility: 1160.26.0388 Boehringer Ingelheim Investigational Site
state: California
city: Carmichael
country: United States
facility: 1160.26.0441 Boehringer Ingelheim Investigational Site
state: California
city: French Camp
country: United States
facility: 1160.26.0145 Boehringer Ingelheim Investigational Site
state: California
city: Fullerton
country: United States
facility: 1160.26.0333 Boehringer Ingelheim Investigational Site
state: California
city: La Jolla
country: United States
facility: 1160.26.0384 Boehringer Ingelheim Investigational Site
state: California
city: La Mesa
country: United States
facility: 1160.26.0091 Boehringer Ingelheim Investigational Site
state: California
city: Lancaster
country: United States
facility: 1160.26.0246 Boehringer Ingelheim Investigational Site
state: California
city: Larkspur
country: United States
facility: 1160.26.0345 Boehringer Ingelheim Investigational Site
state: California
city: Loma Linda
country: United States
facility: 1160.26.0217 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 1160.26.0059 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 1160.26.0088 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 1160.26.0337 Boehringer Ingelheim Investigational Site
state: California
city: Mather
country: United States
facility: 1160.26.0326 Boehringer Ingelheim Investigational Site
state: California
city: Merced
country: United States
facility: 1160.26.0070 Boehringer Ingelheim Investigational Site
state: California
city: Oakland
country: United States
facility: 1160.26.0349 Boehringer Ingelheim Investigational Site
state: California
city: Oceanside
country: United States
facility: 1160.26.0016 Boehringer Ingelheim Investigational Site
state: California
city: Palm Springs
country: United States
facility: 1160.26.0087 Boehringer Ingelheim Investigational Site
state: California
city: Pasadena
country: United States
facility: 1160.26.0459 Boehringer Ingelheim Investigational Site
state: California
city: Redondo Beach
country: United States
facility: 1160.26.0216 Boehringer Ingelheim Investigational Site
state: California
city: Riverside
country: United States
facility: 1160.26.0135 Boehringer Ingelheim Investigational Site
state: California
city: Sacramento
country: United States
facility: 1160.26.0162 Boehringer Ingelheim Investigational Site
state: California
city: Sacramento
country: United States
facility: 1160.26.0300 Boehringer Ingelheim Investigational Site
state: California
city: Sacramento
country: United States
facility: 1160.26.0371 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 1160.26.0116 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 1160.26.0148 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 1160.26.0270 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 1160.26.0284 Boehringer Ingelheim Investigational Site
state: California
city: Santa Ana
country: United States
facility: 1160.26.0351 Boehringer Ingelheim Investigational Site
state: California
city: Santa Rosa
country: United States
facility: 1160.26.0043 Boehringer Ingelheim Investigational Site
state: California
city: Sylmar
country: United States
facility: 1160.26.0462 Boehringer Ingelheim Investigational Site
state: California
city: Torrance
country: United States
facility: 1160.26.0276 Boehringer Ingelheim Investigational Site
state: California
city: Walnut Creek
country: United States
facility: 1160.26.0379 Boehringer Ingelheim Investigational Site
state: California
city: Aurora
country: United States
facility: 1160.26.0419 Boehringer Ingelheim Investigational Site
state: Colorado
city: Colorado Springs
country: United States
facility: 1160.26.0321 Boehringer Ingelheim Investigational Site
state: Colorado
city: Colorado Springs
country: United States
facility: 1160.26.0449 Boehringer Ingelheim Investigational Site
state: Colorado
city: Denver
country: United States
facility: 1160.26.0360 Boehringer Ingelheim Investigational Site
state: Colorado
city: Denver
country: United States
facility: 1160.26.0413 Boehringer Ingelheim Investigational Site
state: Colorado
city: Fort Collins
country: United States
facility: 1160.26.0362 Boehringer Ingelheim Investigational Site
state: Colorado
city: Greeley
country: United States
facility: 1160.26.0399 Boehringer Ingelheim Investigational Site
state: Colorado
city: Bridgeport
country: United States
facility: 1160.26.0058 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Bridgeport
country: United States
facility: 1160.26.0241 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Bridgeport
country: United States
facility: 1160.26.0278 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Fairfield
country: United States
facility: 1160.26.0085 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Guilford
country: United States
facility: 1160.26.0482 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Newark
country: United States
facility: 1160.26.0366 Boehringer Ingelheim Investigational Site
state: Delaware
city: Washington
country: United States
facility: 1160.26.0343 Boehringer Ingelheim Investigational Site
state: District of Columbia
city: Atlantis
country: United States
facility: 1160.26.0022 Boehringer Ingelheim Investigational Site
state: Florida
city: Boynton Beach
country: United States
facility: 1160.26.0382 Boehringer Ingelheim Investigational Site
state: Florida
city: Brandon
country: United States
facility: 1160.26.0056 Boehringer Ingelheim Investigational Site
state: Florida
city: Clearwater
country: United States
facility: 1160.26.0105 Boehringer Ingelheim Investigational Site
state: Florida
city: Clearwater
country: United States
facility: 1160.26.0296 Boehringer Ingelheim Investigational Site
state: Florida
city: Clearwater
country: United States
facility: 1160.26.0429 Boehringer Ingelheim Investigational Site
state: Florida
city: Daytona Beach
country: United States
facility: 1160.26.0376 Boehringer Ingelheim Investigational Site
state: Florida
city: Deerfield Beach
country: United States
facility: 1160.26.0411 Boehringer Ingelheim Investigational Site
state: Florida
city: Fort Myers
country: United States
facility: 1160.26.0074 Boehringer Ingelheim Investigational Site
state: Florida
city: Gainesville
country: United States
facility: 1160.26.0239 Boehringer Ingelheim Investigational Site
state: Florida
city: Hollywood
country: United States
facility: 1160.26.0260 Boehringer Ingelheim Investigational Site
state: Florida
city: Hollywood
country: United States
facility: 1160.26.0265 Boehringer Ingelheim Investigational Site
state: Florida
city: Inverness
country: United States
facility: 1160.26.0100 Boehringer Ingelheim Investigational Site
state: Florida
city: Jacksonville Beach
country: United States
facility: 1160.26.0209 Boehringer Ingelheim Investigational Site
state: Florida
city: Jacksonville
country: United States
facility: 1160.26.0033 Boehringer Ingelheim Investigational Site
state: Florida
city: Jacksonville
country: United States
facility: 1160.26.0089 Boehringer Ingelheim Investigational Site
state: Florida
city: Jacksonville
country: United States
facility: 1160.26.0232 Boehringer Ingelheim Investigational Site
state: Florida
city: Jacksonville
country: United States
facility: 1160.26.0240 Boehringer Ingelheim Investigational Site
state: Florida
city: Jacksonville
country: United States
facility: 1160.26.0427 Boehringer Ingelheim Investigational Site
state: Florida
city: Jacksonville
country: United States
facility: 1160.26.0464 Boehringer Ingelheim Investigational Site
state: Florida
city: Lakeland
country: United States
facility: 1160.26.0012 Boehringer Ingelheim Investigational Site
state: Florida
city: Melbourne
country: United States
facility: 1160.26.0259 Boehringer Ingelheim Investigational Site
state: Florida
city: Melbourne
country: United States
facility: 1160.26.0358 Boehringer Ingelheim Investigational Site
state: Florida
city: Miami
country: United States
facility: 1160.26.0034 Boehringer Ingelheim Investigational Site
state: Florida
city: Miami
country: United States
facility: 1160.26.0199 Boehringer Ingelheim Investigational Site
state: Florida
city: Orlando
country: United States
facility: 1160.26.0227 Boehringer Ingelheim Investigational Site
state: Florida
city: Ormond Beach
country: United States
facility: 1160.26.0095 Boehringer Ingelheim Investigational Site
state: Florida
city: Pensacola
country: United States
facility: 1160.26.0037 Boehringer Ingelheim Investigational Site
state: Florida
city: Pensacola
country: United States
facility: 1160.26.0076 Boehringer Ingelheim Investigational Site
state: Florida
city: Pensacola
country: United States
facility: 1160.26.0081 Boehringer Ingelheim Investigational Site
state: Florida
city: Pensacola
country: United States
facility: 1160.26.0111 Boehringer Ingelheim Investigational Site
state: Florida
city: Port Charlotte
country: United States
facility: 1160.26.0137 Boehringer Ingelheim Investigational Site
state: Florida
city: Port Charlotte
country: United States
facility: 1160.26.0389 Boehringer Ingelheim Investigational Site
state: Florida
city: Port Charlotte
country: United States
facility: 1160.26.0417 Boehringer Ingelheim Investigational Site
state: Florida
city: Rockledge
country: United States
facility: 1160.26.0332 Boehringer Ingelheim Investigational Site
state: Florida
city: Safety Harbor
country: United States
facility: 1160.26.0226 Boehringer Ingelheim Investigational Site
state: Florida
city: Saint Petersburg
country: United States
facility: 1160.26.0015 Boehringer Ingelheim Investigational Site
state: Florida
city: Saint Petersburg
country: United States
facility: 1160.26.0339 Boehringer Ingelheim Investigational Site
state: Florida
city: Sarasota
country: United States
facility: 1160.26.0031 Boehringer Ingelheim Investigational Site
state: Florida
city: Sarasota
country: United States
facility: 1160.26.0385 Boehringer Ingelheim Investigational Site
state: Florida
city: Stuart
country: United States
facility: 1160.26.0010 Boehringer Ingelheim Investigational Site
state: Florida
city: Tamarac
country: United States
facility: 1160.26.0327 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 1160.26.0271 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 1160.26.0328 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 1160.26.0381 Boehringer Ingelheim Investigational Site
state: Florida
city: Vero Beach
country: United States
facility: 1160.26.0019 Boehringer Ingelheim Investigational Site
state: Florida
city: Atlanta
country: United States
facility: 1160.26.0159 Boehringer Ingelheim Investigational Site
state: Georgia
city: Atlanta
country: United States
facility: 1160.26.0283 Boehringer Ingelheim Investigational Site
state: Georgia
city: Atlanta
country: United States
facility: 1160.26.0338 Boehringer Ingelheim Investigational Site
state: Georgia
city: Augusta
country: United States
facility: 1160.26.0021 Boehringer Ingelheim Investigational Site
state: Georgia
city: Augusta
country: United States
facility: 1160.26.0319 Boehringer Ingelheim Investigational Site
state: Georgia
city: Blue Ridge
country: United States
facility: 1160.26.0092 Boehringer Ingelheim Investigational Site
state: Georgia
city: Conyers
country: United States
facility: 1160.26.0161 Boehringer Ingelheim Investigational Site
state: Georgia
city: Coeur d'Alene
country: United States
facility: 1160.26.0026 Boehringer Ingelheim Investigational Site
state: Idaho
city: Berwyn
country: United States
facility: 1160.26.0218 Boehringer Ingelheim Investigational Site
state: Illinois
city: Chicago
country: United States
facility: 1160.26.0184 Boehringer Ingelheim Investigational Site
state: Illinois
city: Chicago
country: United States
facility: 1160.26.0233 Boehringer Ingelheim Investigational Site
state: Illinois
city: Chicago
country: United States
facility: 1160.26.0324 Boehringer Ingelheim Investigational Site
state: Illinois
city: Chicago
country: United States
facility: 1160.26.0457 Boehringer Ingelheim Investigational Site
state: Illinois
city: Evanston
country: United States
facility: 1160.26.0237 Boehringer Ingelheim Investigational Site
state: Illinois
city: Glenview
country: United States
facility: 1160.26.0236 Boehringer Ingelheim Investigational Site
state: Illinois
city: Hines
country: United States
facility: 1160.26.0396 Boehringer Ingelheim Investigational Site
state: Illinois
city: Maywood
country: United States
facility: 1160.26.0438 Boehringer Ingelheim Investigational Site
state: Illinois
city: Melrose Park
country: United States
facility: 1160.26.0331 Boehringer Ingelheim Investigational Site
state: Illinois
city: Normal
country: United States
facility: 1160.26.0364 Boehringer Ingelheim Investigational Site
state: Illinois
city: North Chicago
country: United States
facility: 1160.26.0109 Boehringer Ingelheim Investigational Site
state: Illinois
city: Oak Lawn
country: United States
facility: 1160.26.0152 Boehringer Ingelheim Investigational Site
state: Illinois
city: Rockford
country: United States
facility: 1160.26.0198 Boehringer Ingelheim Investigational Site
state: Illinois
city: Winfield
country: United States
facility: 1160.26.0433 Boehringer Ingelheim Investigational Site
state: Illinois
city: Evansville
country: United States
facility: 1160.26.0041 Boehringer Ingelheim Investigational Site
state: Indiana
city: Fort Wayne
country: United States
facility: 1160.26.0377 Boehringer Ingelheim Investigational Site
state: Indiana
city: Indianapolis
country: United States
facility: 1160.26.0288 Boehringer Ingelheim Investigational Site
state: Indiana
city: Indianapolis
country: United States
facility: 1160.26.0352 Boehringer Ingelheim Investigational Site
state: Indiana
city: Indianapolis
country: United States
facility: 1160.26.0436 Boehringer Ingelheim Investigational Site
state: Indiana
city: Jeffersonville
country: United States
facility: 1160.26.0028 Boehringer Ingelheim Investigational Site
state: Indiana
city: South Bend
country: United States
facility: 1160.26.0235 Boehringer Ingelheim Investigational Site
state: Indiana
city: Dubuque
country: United States
facility: 1160.26.0268 Boehringer Ingelheim Investigational Site
state: Iowa
city: West Des Moines
country: United States
facility: 1160.26.0001 Boehringer Ingelheim Investigational Site
state: Iowa
city: West Des Moines
country: United States
facility: 1160.26.0189 Boehringer Ingelheim Investigational Site
state: Iowa
city: West Des Moines
country: United States
facility: 1160.26.0357 Boehringer Ingelheim Investigational Site
state: Iowa
city: Wichita
country: United States
facility: 1160.26.0354 Boehringer Ingelheim Investigational Site
state: Kansas
city: Bowling Green
country: United States
facility: 1160.26.0077 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Crestview Hills
country: United States
facility: 1160.26.0138 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Lexington
country: United States
facility: 1160.26.0422 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Louisville
country: United States
facility: 1160.26.0178 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Louisville
country: United States
facility: 1160.26.0397 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Owensboro
country: United States
facility: 1160.26.0310 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Baton Rouge
country: United States
facility: 1160.26.0011 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Baton Rouge
country: United States
facility: 1160.26.0144 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Baton Rouge
country: United States
facility: 1160.26.0404 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Covington
country: United States
facility: 1160.26.0093 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Lacombe
country: United States
facility: 1160.26.0340 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Lafayette
country: United States
facility: 1160.26.0018 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Lafayette
country: United States
facility: 1160.26.0391 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Morgan City
country: United States
facility: 1160.26.0252 Boehringer Ingelheim Investigational Site
state: Louisiana
city: New Iberia
country: United States
facility: 1160.26.0132 Boehringer Ingelheim Investigational Site
state: Louisiana
city: New Orleans
country: United States
facility: 1160.26.0299 Tulane University School Of Medicine
state: Louisiana
city: Shreveport
country: United States
facility: 1160.26.0048 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Auburn
country: United States
facility: 1160.26.0096 Boehringer Ingelheim Investigational Site
state: Maine
city: Scarborough
country: United States
facility: 1160.26.0068 Boehringer Ingelheim Investigational Site
state: Maine
city: Annapolis
country: United States
facility: 1160.26.0114 Boehringer Ingelheim Investigational Site
state: Maryland
city: Annapolis
country: United States
facility: 1160.26.0164 Boehringer Ingelheim Investigational Site
state: Maryland
city: Baltimore
country: United States
facility: 1160.26.0023 Boehringer Ingelheim Investigational Site
state: Maryland
city: Baltimore
country: United States
facility: 1160.26.0047 Boehringer Ingelheim Investigational Site
state: Maryland
city: Baltimore
country: United States
facility: 1160.26.0079 Boehringer Ingelheim Investigational Site
state: Maryland
city: Baltimore
country: United States
facility: 1160.26.0186 Boehringer Ingelheim Investigational Site
state: Maryland
city: Baltimore
country: United States
facility: 1160.26.0194 Boehringer Ingelheim Investigational Site
state: Maryland
city: Bel Air
country: United States
facility: 1160.26.0255 Boehringer Ingelheim Investigational Site
state: Maryland
city: Columbia
country: United States
facility: 1160.26.0398 Boehringer Ingelheim Investigational Site
state: Maryland
city: Rockville
country: United States
facility: 1160.26.0177 Boehringer Ingelheim Investigational Site
state: Maryland
city: Salisbury
country: United States
facility: 1160.26.0073 Boehringer Ingelheim Investigational Site
state: Maryland
city: Salisbury
country: United States
facility: 1160.26.0207 Boehringer Ingelheim Investigational Site
state: Maryland
city: Takoma Park
country: United States
facility: 1160.26.0196 Boehringer Ingelheim Investigational Site
state: Maryland
city: Towson
country: United States
facility: 1160.26.0187 Boehringer Ingelheim Investigational Site
state: Maryland
city: Westminster
country: United States
facility: 1160.26.0052 Boehringer Ingelheim Investigational Site
state: Maryland
city: Ayer
country: United States
facility: 1160.26.0042 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Boston
country: United States
facility: 1160.26.0401 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: East Bridgewater
country: United States
facility: 1160.26.0160 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Haverhill
country: United States
facility: 1160.26.0443 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Haverhill
country: United States
facility: 1160.26.0452 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Natick
country: United States
facility: 1160.26.0029 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Newtown
country: United States
facility: 1160.26.0446 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: North Dartmouth
country: United States
facility: 1160.26.0003 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Northborough
country: United States
facility: 1160.26.0470 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Worcester
country: United States
facility: 1160.26.0308 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Bloomfield Hills
country: United States
facility: 1160.26.0141 Boehringer Ingelheim Investigational Site
state: Michigan
city: Detroit
country: United States
facility: 1160.26.0225 Boehringer Ingelheim Investigational Site
state: Michigan
city: Grand Blanc
country: United States
facility: 1160.26.0154 Boehringer Ingelheim Investigational Site
state: Michigan
city: Grand Rapids
country: United States
facility: 1160.26.0030 Boehringer Ingelheim Investigational Site
state: Michigan
city: Kalamazoo
country: United States
facility: 1160.26.0171 Boehringer Ingelheim Investigational Site
state: Michigan
city: Lapeer
country: United States
facility: 1160.26.0205 Boehringer Ingelheim Investigational Site
state: Michigan
city: Muskegon
country: United States
facility: 1160.26.0279 Boehringer Ingelheim Investigational Site
state: Michigan
city: Petoskey
country: United States
facility: 1160.26.0445 Boehringer Ingelheim Investigational Site
state: Michigan
city: Rochester Hills
country: United States
facility: 1160.26.0274 Boehringer Ingelheim Investigational Site
state: Michigan
city: Saginaw
country: United States
facility: 1160.26.0165 Boehringer Ingelheim Investigational Site
state: Michigan
city: Troy
country: United States
facility: 1160.26.0020 Boehringer Ingelheim Investigational Site
state: Michigan
city: Ypsilanti
country: United States
facility: 1160.26.0188 Boehringer Ingelheim Investigational Site
state: Michigan
city: Minneapolis
country: United States
facility: 1160.26.0131 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Minneapolis
country: United States
facility: 1160.26.0421 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Robbinsdale
country: United States
facility: 1160.26.0202 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Saint Paul
country: United States
facility: 1160.26.0101 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Gulfport
country: United States
facility: 1160.26.0086 Boehringer Ingelheim Investigational Site
state: Mississippi
city: Tupelo
country: United States
facility: 1160.26.0119 Boehringer Ingelheim Investigational Site
state: Mississippi
city: Columbia
country: United States
facility: 1160.26.0055 Boehringer Ingelheim Investigational Site
state: Missouri
city: Columbia
country: United States
facility: 1160.26.0172 Boehringer Ingelheim Investigational Site
state: Missouri
city: Kansas City
country: United States
facility: 1160.26.0257 Boehringer Ingelheim Investigational Site
state: Missouri
city: Kansas City
country: United States
facility: 1160.26.0266 Boehringer Ingelheim Investigational Site
state: Missouri
city: Saint Charles
country: United States
facility: 1160.26.0336 Boehringer Ingelheim Investigational Site
state: Missouri
city: Saint Louis
country: United States
facility: 1160.26.0249 Boehringer Ingelheim Investigational Site
state: Missouri
city: Kalispell
country: United States
facility: 1160.26.0027 Boehringer Ingelheim Investigational Site
state: Montana
city: Alliance
country: United States
facility: 1160.26.0128 Boehringer Ingelheim Investigational Site
state: Nebraska
city: Omaha
country: United States
facility: 1160.26.0110 Boehringer Ingelheim Investigational Site
state: Nebraska
city: Papillion
country: United States
facility: 1160.26.0355 Boehringer Ingelheim Investigational Site
state: Nebraska
city: Henderson
country: United States
facility: 1160.26.0346 Boehringer Ingelheim Investigational Site
state: Nevada
city: Las Vegas
country: United States
facility: 1160.26.0066 Boehringer Ingelheim Investigational Site
state: Nevada
city: Las Vegas
country: United States
facility: 1160.26.0174 Boehringer Ingelheim Investigational Site
state: Nevada
city: Las Vegas
country: United States
facility: 1160.26.0430 Boehringer Ingelheim Investigational Site
state: Nevada
city: Lebanon
country: United States
facility: 1160.26.0190 Boehringer Ingelheim Investigational Site
state: New Hampshire
city: Browns Mills
country: United States
facility: 1160.26.0142 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Cherry Hill
country: United States
facility: 1160.26.0125 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Elmer
country: United States
facility: 1160.26.0432 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Englewood
country: United States
facility: 1160.26.0448 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Flemington
country: United States
facility: 1160.26.0248 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Haddon Heights
country: United States
facility: 1160.26.0244 Boehringer Ingelheim Investigational Site
state: New Jersey
city: New Brunswick
country: United States
facility: 1160.26.0243 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Oakland
country: United States
facility: 1160.26.0478 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Ocean City
country: United States
facility: 1160.26.0392 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Paterson
country: United States
facility: 1160.26.0472 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Voorhees
country: United States
facility: 1160.26.0221 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Westwood
country: United States
facility: 1160.26.0254 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Albuquerque
country: United States
facility: 1160.26.0127 Boehringer Ingelheim Investigational Site
state: New Mexico
city: Albuquerque
country: United States
facility: 1160.26.0423 Boehringer Ingelheim Investigational Site
state: New Mexico
city: Albany
country: United States
facility: 1160.26.0476 Boehringer Ingelheim Investigational Site
state: New York
city: Bronx
country: United States
facility: 1160.26.0113 Boehringer Ingelheim Investigational Site
state: New York
city: Bronx
country: United States
facility: 1160.26.0281 Boehringer Ingelheim Investigational Site
state: New York
city: Buffalo
country: United States
facility: 1160.26.0063 Boehringer Ingelheim Investigational Site
state: New York
city: Cortlandt Manor
country: United States
facility: 1160.26.0044 Boehringer Ingelheim Investigational Site
state: New York
city: Flushing
country: United States
facility: 1160.26.0373 Boehringer Ingelheim Investigational Site
state: New York
city: Garden City
country: United States
facility: 1160.26.0045 Boehringer Ingelheim Investigational Site
state: New York
city: Kingston
country: United States
facility: 1160.26.0251 Boehringer Ingelheim Investigational Site
state: New York
city: Mineola
country: United States
facility: 1160.26.0229 Boehringer Ingelheim Investigational Site
state: New York
city: Mineola
country: United States
facility: 1160.26.0451 Boehringer Ingelheim Investigational Site
state: New York
city: New Hyde Park
country: United States
facility: 1160.26.0090 Boehringer Ingelheim Investigational Site
state: New York
city: New Rochelle
country: United States
facility: 1160.26.0183 Boehringer Ingelheim Investigational Site
state: New York
city: New York
country: United States
facility: 1160.26.0316 Boehringer Ingelheim Investigational Site
state: New York
city: North Massapequa
country: United States
facility: 1160.26.0146 Boehringer Ingelheim Investigational Site
state: New York
city: Northport
country: United States
facility: 1160.26.0210 Boehringer Ingelheim Investigational Site
state: New York
city: Poughkeepsie
country: United States
facility: 1160.26.0075 Boehringer Ingelheim Investigational Site
state: New York
city: Rochester
country: United States
facility: 1160.26.0197 Boehringer Ingelheim Investigational Site
state: New York
city: Rochester
country: United States
facility: 1160.26.0320 Boehringer Ingelheim Investigational Site
state: New York
city: Scarsdale
country: United States
facility: 1160.26.0064 Boehringer Ingelheim Investigational Site
state: New York
city: Troy
country: United States
facility: 1160.26.0414 Boehringer Ingelheim Investigational Site
state: New York
city: Watertown
country: United States
facility: 1160.26.0356 Boehringer Ingelheim Investigational Site
state: New York
city: Williamsville
country: United States
facility: 1160.26.0039 Boehringer Ingelheim Investigational Site
state: New York
city: Asheville
country: United States
facility: 1160.26.0353 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Charlotte
country: United States
facility: 1160.26.0080 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Charlotte
country: United States
facility: 1160.26.0412 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Gastonia
country: United States
facility: 1160.26.0350 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Greensboro
country: United States
facility: 1160.26.0322 Boehringer Ingelheim Investigational Site
state: North Carolina
city: High Point
country: United States
facility: 1160.26.0173 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Lexington
country: United States
facility: 1160.26.0108 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Pinehurst
country: United States
facility: 1160.26.0006 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Statesville
country: United States
facility: 1160.26.0002 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Statesville
country: United States
facility: 1160.26.0069 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Wilmington
country: United States
facility: 1160.26.0372 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Winston-Salem
country: United States
facility: 1160.26.0094 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Winston-Salem
country: United States
facility: 1160.26.0425 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Grand Forks
country: United States
facility: 1160.26.0102 Boehringer Ingelheim Investigational Site
state: North Dakota
city: Jamestown
country: United States
facility: 1160.26.0222 Boehringer Ingelheim Investigational Site
state: North Dakota
city: Akron
country: United States
facility: 1160.26.0203 Boehringer Ingelheim Investigational Site
state: Ohio
city: Canal Fulton
country: United States
facility: 1160.26.0434 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 1160.26.0083 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 1160.26.0402 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 1160.26.0426 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 1160.26.0479 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cleveland
country: United States
facility: 1160.26.0263 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cleveland
country: United States
facility: 1160.26.0480 Boehringer Ingelheim Investigational Site
state: Ohio
city: Columbus
country: United States
facility: 1160.26.0267 Boehringer Ingelheim Investigational Site
state: Ohio
city: Dayton
country: United States
facility: 1160.26.0035 Boehringer Ingelheim Investigational Site
state: Ohio
city: Fairview Park
country: United States
facility: 1160.26.0150 Boehringer Ingelheim Investigational Site
state: Ohio
city: Kettering
country: United States
facility: 1160.26.0201 Boehringer Ingelheim Investigational Site
state: Ohio
city: Lorain
country: United States
facility: 1160.26.0223 Boehringer Ingelheim Investigational Site
state: Ohio
city: Lyndhurst
country: United States
facility: 1160.26.0214 Boehringer Ingelheim Investigational Site
state: Ohio
city: Sandusky
country: United States
facility: 1160.26.0275 Boehringer Ingelheim Investigational Site
state: Ohio
city: Westlake
country: United States
facility: 1160.26.0103 Boehringer Ingelheim Investigational Site
state: Ohio
city: Bartlesville
country: United States
facility: 1160.26.0155 Boehringer Ingelheim Investigational Site
state: Oklahoma
city: Tulsa
country: United States
facility: 1160.26.0435 Boehringer Ingelheim Investigational Site
state: Oklahoma
city: Corvallis
country: United States
facility: 1160.26.0139 Boehringer Ingelheim Investigational Site
state: Oregon
city: Eugene
country: United States
facility: 1160.26.0325 Boehringer Ingelheim Investigational Site
state: Oregon
city: Hillsboro
country: United States
facility: 1160.26.0078 Boehringer Ingelheim Investigational Site
state: Oregon
city: Portland
country: United States
facility: 1160.26.0245 Boehringer Ingelheim Investigational Site
state: Oregon
city: Springfield
country: United States
facility: 1160.26.0133 Boehringer Ingelheim Investigational Site
state: Oregon
city: Allentown
country: United States
facility: 1160.26.0301 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Altoona
country: United States
facility: 1160.26.0454 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Camp Hill
country: United States
facility: 1160.26.0295 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Hershey
country: United States
facility: 1160.26.0294 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Jenkintown
country: United States
facility: 1160.26.0369 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Jersey Shore
country: United States
facility: 1160.26.0303 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Lancaster
country: United States
facility: 1160.26.0431 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Langhorne
country: United States
facility: 1160.26.0168 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Meadowbrook
country: United States
facility: 1160.26.0293 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Newton
country: United States
facility: 1160.26.0025 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Norristown
country: United States
facility: 1160.26.0394 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 1160.26.0158 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 1160.26.0181 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 1160.26.0416 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Pittsburgh
country: United States
facility: 1160.26.0344 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Pittsburgh
country: United States
facility: 1160.26.0466 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Sellersville
country: United States
facility: 1160.26.0208 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Uniontown
country: United States
facility: 1160.26.0465 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Upland
country: United States
facility: 1160.26.0400 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Wynnewood
country: United States
facility: 1160.26.0032 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Wyomissing
country: United States
facility: 1160.26.0067 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Pawtucket
country: United States
facility: 1160.26.0212 Boehringer Ingelheim Investigational Site
state: Rhode Island
city: Beaufort
country: United States
facility: 1160.26.0007 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Charleston
country: United States
facility: 1160.26.0383 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Greenville
country: United States
facility: 1160.26.0313 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Mount Pleasant
country: United States
facility: 1160.26.0450 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Spartanburg
country: United States
facility: 1160.26.0166 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Summerville
country: United States
facility: 1160.26.0008 Boehringer Ingelheim Investigational Site
state: South Carolina
city: West Columbia
country: United States
facility: 1160.26.0468 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Rapid City
country: United States
facility: 1160.26.0348 Boehringer Ingelheim Investigational Site
state: South Dakota
city: Chattanooga
country: United States
facility: 1160.26.0084 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Germantown
country: United States
facility: 1160.26.0062 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Johnson City
country: United States
facility: 1160.26.0370 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Nashville
country: United States
facility: 1160.26.0323 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Nashville
country: United States
facility: 1160.26.0395 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Oak Ridge
country: United States
facility: 1160.26.0474 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Austin
country: United States
facility: 1160.26.0129 Boehringer Ingelheim Investigational Site
state: Texas
city: Austin
country: United States
facility: 1160.26.0410 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 1160.26.0156 Boehringer Ingelheim Investigational Site
state: Texas
city: Fort Worth
country: United States
facility: 1160.26.0315 Boehringer Ingelheim Investigational Site
state: Texas
city: Fort Worth
country: United States
facility: 1160.26.0444 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 1160.26.0447 Boehringer Ingelheim Investigational Site
state: Texas
city: Killeen
country: United States
facility: 1160.26.0483 Boehringer Ingelheim Investigational Site
state: Texas
city: Lubbock
country: United States
facility: 1160.26.0335 Boehringer Ingelheim Investigational Site
state: Texas
city: McKinney
country: United States
facility: 1160.26.0230 Boehringer Ingelheim Investigational Site
state: Texas
city: Plano
country: United States
facility: 1160.26.0467 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 1160.26.0013 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 1160.26.0269 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 1160.26.0307 Boehringer Ingelheim Investigational Site
state: Texas
city: San Marcos
country: United States
facility: 1160.26.0285 Boehringer Ingelheim Investigational Site
state: Texas
city: Tyler
country: United States
facility: 1160.26.0215 Boehringer Ingelheim Investigational Site
state: Texas
city: Tyler
country: United States
facility: 1160.26.0367 Boehringer Ingelheim Investigational Site
state: Texas
city: Arlington
country: United States
facility: 1160.26.0195 Boehringer Ingelheim Investigational Site
state: Virginia
city: Charlottesville
country: United States
facility: 1160.26.0453 Boehringer Ingelheim Investigational Site
state: Virginia
city: Chesapeake
country: United States
facility: 1160.26.0053 Boehringer Ingelheim Investigational Site
state: Virginia
city: Danville
country: United States
facility: 1160.26.0098 Boehringer Ingelheim Investigational Site
state: Virginia
city: Falls Church
country: United States
facility: 1160.26.0386 Boehringer Ingelheim Investigational Site
state: Virginia
city: Fredericksburg
country: United States
facility: 1160.26.0428 Boehringer Ingelheim Investigational Site
state: Virginia
city: Harrisonburg
country: United States
facility: 1160.26.0311 Boehringer Ingelheim Investigational Site
state: Virginia
city: Newport News
country: United States
facility: 1160.26.0292 Boehringer Ingelheim Investigational Site
state: Virginia
city: Norfolk
country: United States
facility: 1160.26.0224 Boehringer Ingelheim Investigational Site
state: Virginia
city: Salem
country: United States
facility: 1160.26.0220 Boehringer Ingelheim Investigational Site
state: Virginia
city: Winchester
country: United States
facility: 1160.26.0317 Boehringer Ingelheim Investigational Site
state: Virginia
city: Bellevue
country: United States
facility: 1160.26.0287 Boehringer Ingelheim Investigational Site
state: Washington
city: Bellingham
country: United States
facility: 1160.26.0050 Boehringer Ingelheim Investigational Site
state: Washington
city: Burien
country: United States
facility: 1160.26.0040 Boehringer Ingelheim Investigational Site
state: Washington
city: Olympia
country: United States
facility: 1160.26.0298 Boehringer Ingelheim Investigational Site
state: Washington
city: Spokane
country: United States
facility: 1160.26.0250 Boehringer Ingelheim Investigational Site
state: Washington
city: Tacoma
country: United States
facility: 1160.26.0256 Boehringer Ingelheim Investigational Site
state: Washington
city: Wenatchee
country: United States
facility: 1160.26.0024 Boehringer Ingelheim Investigational Site
state: Washington
city: Charleston
country: United States
facility: 1160.26.0193 Boehringer Ingelheim Investigational Site
state: West Virginia
city: Clarksburg
country: United States
facility: 1160.26.0169 Boehringer Ingelheim Investigational Site
state: West Virginia
city: Huntington
country: United States
facility: 1160.26.0365 Boehringer Ingelheim Investigational Site
state: West Virginia
city: Elkhorn
country: United States
facility: 1160.26.0072 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Green Bay
country: United States
facility: 1160.26.0234 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Madison
country: United States
facility: 1160.26.0099 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Madison
country: United States
facility: 1160.26.0242 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Marshfield
country: United States
facility: 1160.26.0359 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Milwaukee
country: United States
facility: 1160.26.0461 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Bahía Blanca
country: Argentina
facility: 1160.26.0523 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 1160.26.0524 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 1160.26.0533 Boehringer Ingelheim Investigational Site
city: Cipolletti
country: Argentina
facility: 1160.26.0526 Boehringer Ingelheim Investigational Site
city: Coronel Suárez
country: Argentina
facility: 1160.26.0529 Boehringer Ingelheim Investigational Site
city: Córdoba
country: Argentina
facility: 1160.26.0531 Boehringer Ingelheim Investigational Site
city: La Plata
country: Argentina
facility: 1160.26.0530 Boehringer Ingelheim Investigational Site
city: Mar del Plata
country: Argentina
facility: 1160.26.0527 Boehringer Ingelheim Investigational Site
city: Mar del Plata
country: Argentina
facility: 1160.26.0532 Boehringer Ingelheim Investigational Site
city: Quilmes
country: Argentina
facility: 1160.26.0525 Boehringer Ingelheim Investigational Site
city: Rosario
country: Argentina
facility: 1160.26.0521 Boehringer Ingelheim Investigational Site
city: Salta
country: Argentina
facility: 1160.26.0528 Boehringer Ingelheim Investigational Site
city: Santa Fe
country: Argentina
facility: 1160.26.0522 Boehringer Ingelheim Investigational Site
city: Coffs Harbour
country: Australia
facility: 1160.26.0508 Boehringer Ingelheim Investigational Site
state: New South Wales
city: Gosford
country: Australia
facility: 1160.26.0510 Boehringer Ingelheim Investigational Site
state: New South Wales
city: Herston
country: Australia
facility: 1160.26.0505 Boehringer Ingelheim Investigational Site
state: Queensland
city: Milton
country: Australia
facility: 1160.26.0506 Boehringer Ingelheim Investigational Site
state: Queensland
city: Ashford
country: Australia
facility: 1160.26.0509 Boehringer Ingelheim Investigational Site
state: South Australia
city: Launceston
country: Australia
facility: 1160.26.0507 Boehringer Ingelheim Investigational Site
state: Tasmania
city: Box Hill
country: Australia
facility: 1160.26.0504 Boehringer Ingelheim Investigational Site
state: Victoria
city: Geelong
country: Australia
facility: 1160.26.0501 Boehringer Ingelheim Investigational Site
state: Victoria
city: Parkville
country: Australia
facility: 1160.26.0502 Boehringer Ingelheim Investigational Site
state: Victoria
city: Prahran
country: Australia
facility: 1160.26.0503 Boehringer Ingelheim Investigational Site
state: Victoria
city: Graz
country: Austria
facility: 1160.26.0543 Boehringer Ingelheim Investigational Site
city: Linz
country: Austria
facility: 1160.26.0549 Boehringer Ingelheim Investigational Site
city: Wels
country: Austria
facility: 1160.26.0546 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1160.26.0541 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1160.26.0542 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1160.26.0544 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1160.26.0545 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1160.26.0547 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1160.26.0548 Boehringer Ingelheim Investigational Site
city: Wr. Neustadt
country: Austria
facility: 1160.26.0550 Boehringer Ingelheim Investigational Site
city: Aalst
country: Belgium
facility: 1160.26.0564 Boehringer Ingelheim Investigational Site
city: Antwerpen
country: Belgium
facility: 1160.26.0573 Boehringer Ingelheim Investigational Site
city: Antwerpen
country: Belgium
facility: 1160.26.0575 Boehringer Ingelheim Investigational Site
city: Brasschaat
country: Belgium
facility: 1160.26.0572 Boehringer Ingelheim Investigational Site
city: Brugge
country: Belgium
facility: 1160.26.0577 Boehringer Ingelheim Investigational Site
city: Brussels
country: Belgium
facility: 1160.26.0571 Boehringer Ingelheim Investigational Site
city: Bruxelles
country: Belgium
facility: 1160.26.0581 Boehringer Ingelheim Investigational Site
city: Bruxelles
country: Belgium
facility: 1160.26.0585 Boehringer Ingelheim Investigational Site
city: Bruxelles
country: Belgium
facility: 1160.26.0586 Boehringer Ingelheim Investigational Site
city: Edegem
country: Belgium
facility: 1160.26.0563 Boehringer Ingelheim Investigational Site
city: Genk
country: Belgium
facility: 1160.26.0578 Boehringer Ingelheim Investigational Site
city: Genk
country: Belgium
facility: 1160.26.0587 Boehringer Ingelheim Investigational Site
city: Gent
country: Belgium
facility: 1160.26.0574 Boehringer Ingelheim Investigational Site
city: Gilly
country: Belgium
facility: 1160.26.0588 Boehringer Ingelheim Investigational Site
city: Haine-St.-Paul
country: Belgium
facility: 1160.26.0580 Boehringer Ingelheim Investigational Site
city: Hasselt
country: Belgium
facility: 1160.26.0568 Boehringer Ingelheim Investigational Site
city: Kortrijk
country: Belgium
facility: 1160.26.0569 Boehringer Ingelheim Investigational Site
city: Leuven
country: Belgium
facility: 1160.26.0561 Boehringer Ingelheim Investigational Site
city: Liège
country: Belgium
facility: 1160.26.0579 Boehringer Ingelheim Investigational Site
city: Liège
country: Belgium
facility: 1160.26.0583 Boehringer Ingelheim Investigational Site
city: Mol
country: Belgium
facility: 1160.26.0589 Boehringer Ingelheim Investigational Site
city: Oostende
country: Belgium
facility: 1160.26.0567 Boehringer Ingelheim Investigational Site
city: Roeselare
country: Belgium
facility: 1160.26.0570 Boehringer Ingelheim Investigational Site
city: Tienen
country: Belgium
facility: 1160.26.0566 Boehringer Ingelheim Investigational Site
city: Turnhout
country: Belgium
facility: 1160.26.0562 Boehringer Ingelheim Investigational Site
city: Belo Horizonte
country: Brazil
facility: 1160.26.550648 Boehringer Ingelheim Investigational Site
city: Blumenau
country: Brazil
facility: 1160.26.550654 Boehringer Ingelheim Investigational Site
city: Campinas
country: Brazil
facility: 1160.26.550644 Boehringer Ingelheim Investigational Site
city: Curitiba
country: Brazil
facility: 1160.26.550650 Boehringer Ingelheim Investigational Site
city: Curitiba
country: Brazil
facility: 1160.26.550651 Boehringer Ingelheim Investigational Site
city: Curitiba
country: Brazil
facility: 1160.26.550653 Boehringer Ingelheim Investigational Site
city: Goiania
country: Brazil
facility: 1160.26.550652 Boehringer Ingelheim Investigational Site
city: Marília
country: Brazil
facility: 1160.26.550645 Boehringer Ingelheim Investigational Site
city: São José do Rio Preto
country: Brazil
facility: 1160.26.550646 Boehringer Ingelheim Investigational Site
city: São José do Rio Preto
country: Brazil
facility: 1160.26.550647 Boehringer Ingelheim Investigational Site
city: São Paulo
country: Brazil
facility: 1160.26.550641 Boehringer Ingelheim Investigational Site
city: São Paulo
country: Brazil
facility: 1160.26.550642 Boehringer Ingelheim Investigational Site
city: São Paulo
country: Brazil
facility: 1160.26.550643 Boehringer Ingelheim Investigational Site
city: Uberaba
country: Brazil
facility: 1160.26.550649 Boehringer Ingelheim Investigational Site
city: Pleven
country: Bulgaria
facility: 1160.26.0620 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0611 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0612 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0613 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0614 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0615 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0616 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0617 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0618 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0622 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0623 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0624 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 1160.26.0625 Boehringer Ingelheim Investigational Site
city: Stara Zagora
country: Bulgaria
facility: 1160.26.0626 Boehringer Ingelheim Investigational Site
city: Varna
country: Bulgaria
facility: 1160.26.0621 Boehringer Ingelheim Investigational Site
city: Calgary
country: Canada
facility: 1160.26.0694 Boehringer Ingelheim Investigational Site
state: Alberta
city: Calgary
country: Canada
facility: 1160.26.0696 Boehringer Ingelheim Investigational Site
state: Alberta
city: Coquitlam
country: Canada
facility: 1160.26.0680 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Coquitlam
country: Canada
facility: 1160.26.0712 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Kelowna
country: Canada
facility: 1160.26.0706 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Nanaimo
country: Canada
facility: 1160.26.0725 Boehringer Ingelheim Investigational Site
state: British Columbia
city: New Westminster
country: Canada
facility: 1160.26.0691 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Victoria
country: Canada
facility: 1160.26.0714 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Portage la Prairie
country: Canada
facility: 1160.26.0701 Boehringer Ingelheim Investigational Site
state: Manitoba
city: Winnipeg
country: Canada
facility: 1160.26.0698 Boehringer Ingelheim Investigational Site
state: Manitoba
city: Bay Roberts
country: Canada
facility: 1160.26.0707 Boehringer Ingelheim Investigational Site
state: Newfoundland and Labrador
city: Antigonish
country: Canada
facility: 1160.26.0676 Boehringer Ingelheim Investigational Site
state: Nova Scotia
city: Halifax
country: Canada
facility: 1160.26.0703 Boehringer Ingelheim Investigational Site
state: Nova Scotia
city: Ajax
country: Canada
facility: 1160.26.0679 Boehringer Ingelheim Investigational Site
state: Ontario
city: Brampton
country: Canada
facility: 1160.26.0677 Boehringer Ingelheim Investigational Site
state: Ontario
city: Burlington
country: Canada
facility: 1160.26.0674 Boehringer Ingelheim Investigational Site
state: Ontario
city: Cambridge
country: Canada
facility: 1160.26.0702 Boehringer Ingelheim Investigational Site
state: Ontario
city: Cambridge
country: Canada
facility: 1160.26.0720 Boehringer Ingelheim Investigational Site
state: Ontario
city: Etobicoke
country: Canada
facility: 1160.26.0671 Clinical Research & Diagnostic Solutions Inc.
state: Ontario
city: Grimsby
country: Canada
facility: 1160.26.0692 Boehringer Ingelheim Investigational Site
state: Ontario
city: Hamilton
country: Canada
facility: 1160.26.0685 Boehringer Ingelheim Investigational Site
state: Ontario
city: Hamilton
country: Canada
facility: 1160.26.0697 Boehringer Ingelheim Investigational Site
state: Ontario
city: Hamilton
country: Canada
facility: 1160.26.0710 Boehringer Ingelheim Investigational Site
state: Ontario
city: Hamilton
country: Canada
facility: 1160.26.0719 Boehringer Ingelheim Investigational Site
state: Ontario
city: Hamilton
country: Canada
facility: 1160.26.0721 Boehringer Ingelheim Investigational Site
state: Ontario
city: Kitchener
country: Canada
facility: 1160.26.0689 Boehringer Ingelheim Investigational Site
state: Ontario
city: Mississauga
country: Canada
facility: 1160.26.0695 Boehringer Ingelheim Investigational Site
state: Ontario
city: Mississauga
country: Canada
facility: 1160.26.0708 Boehringer Ingelheim Investigational Site
state: Ontario
city: Mississauga
country: Canada
facility: 1160.26.0724 Boehringer Ingelheim Investigational Site
state: Ontario
city: Newmarket
country: Canada
facility: 1160.26.0688 Boehringer Ingelheim Investigational Site
state: Ontario
city: Oshawa
country: Canada
facility: 1160.26.0672 Boehringer Ingelheim Investigational Site
state: Ontario
city: Ottawa
country: Canada
facility: 1160.26.0687 Boehringer Ingelheim Investigational Site
state: Ontario
city: Scarborough
country: Canada
facility: 1160.26.0723 Boehringer Ingelheim Investigational Site
state: Ontario
city: Sudbury
country: Canada
facility: 1160.26.0715 Boehringer Ingelheim Investigational Site
state: Ontario
city: Thunder Bay
country: Canada
facility: 1160.26.0690 Boehringer Ingelheim Investigational Site
state: Ontario
city: Toronto
country: Canada
facility: 1160.26.0684 Boehringer Ingelheim Investigational Site
state: Ontario
city: Toronto
country: Canada
facility: 1160.26.0718 Boehringer Ingelheim Investigational Site
state: Ontario
city: Waterloo
country: Canada
facility: 1160.26.0711 Boehringer Ingelheim Investigational Site
state: Ontario
city: Windsor
country: Canada
facility: 1160.26.0686 Boehringer Ingelheim Investigational Site
state: Ontario
city: Longueuil
country: Canada
facility: 1160.26.0693 Boehringer Ingelheim Investigational Site
state: Quebec
city: Montreal
country: Canada
facility: 1160.26.0681 Boehringer Ingelheim Investigational Site
state: Quebec
city: Montreal
country: Canada
facility: 1160.26.0683 Boehringer Ingelheim Investigational Site
state: Quebec
city: Montreal
country: Canada
facility: 1160.26.0705 Boehringer Ingelheim Investigational Site
state: Quebec
city: Montreal
country: Canada
facility: 1160.26.0709 Boehringer Ingelheim Investigational Site
state: Quebec
city: Montreal
country: Canada
facility: 1160.26.0716 Boehringer Ingelheim Investigational Site
state: Quebec
city: Quebec City
country: Canada
facility: 1160.26.0717 Boehringer Ingelheim Investigational Site
state: Quebec
city: Saint George-de-Beauce
country: Canada
facility: 1160.26.0713 Boehringer Ingelheim Investigational Site
state: Quebec
city: Saint Jerome
country: Canada
facility: 1160.26.0704 Boehringer Ingelheim Investigational Site
state: Quebec
city: St. Charles-Borromee
country: Canada
facility: 1160.26.0699 Boehringer Ingelheim Investigational Site
state: Quebec
city: St. Hyacinthe
country: Canada
facility: 1160.26.0675 Boehringer Ingelheim Investigational Site
state: Quebec
city: Ste-Foy
country: Canada
facility: 1160.26.0700 Boehringer Ingelheim Investigational Site
state: Quebec
city: Terrebonne (Lachenaie)
country: Canada
facility: 1160.26.0682 Boehringer Ingelheim Investigational Site
state: Quebec
city: Saskatoon
country: Canada
facility: 1160.26.0673 Boehringer Ingelheim Investigational Site
state: Saskatchewan
city: Saskatoon
country: Canada
facility: 1160.26.0678 Boehringer Ingelheim Investigational Site
state: Saskatchewan
city: Beijing
country: China
facility: 1160.26.0771 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 1160.26.0772 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 1160.26.0773 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 1160.26.0774 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 1160.26.0775 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 1160.26.0783 Boehringer Ingelheim Investigational Site
city: Hangzhou
country: China
facility: 1160.26.0784 Boehringer Ingelheim Investigational Site
city: Harbin
country: China
facility: 1160.26.0776 Boehringer Ingelheim Investigational Site
city: QingDao
country: China
facility: 1160.26.0778 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 1160.26.0781 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 1160.26.0782 Boehringer Ingelheim Investigational Site
city: Shenyang
country: China
facility: 1160.26.0777 Boehringer Ingelheim Investigational Site
city: Shijiazhuang
country: China
facility: 1160.26.0780 Boehringer Ingelheim Investigational Site
city: Bogotá
country: Colombia
facility: 1160.26.0801 Boehringer Ingelheim Investigational Site
city: Bogotá
country: Colombia
facility: 1160.26.0802 Boehringer Ingelheim Investigational Site
city: Bogotá
country: Colombia
facility: 1160.26.0803 Boehringer Ingelheim Investigational Site
city: Brno
country: Czechia
facility: 1160.26.0815 Boehringer Ingelheim Investigational Site
city: Brno
country: Czechia
facility: 1160.26.0816 Boehringer Ingelheim Investigational Site
city: Ostrava 1
country: Czechia
facility: 1160.26.0820 Boehringer Ingelheim Investigational Site
city: Pardubice
country: Czechia
facility: 1160.26.0818 Boehringer Ingelheim Investigational Site
city: Plzen-Bory
country: Czechia
facility: 1160.26.0814 Boehringer Ingelheim Investigational Site
city: Pragha 9
country: Czechia
facility: 1160.26.0813 Boehringer Ingelheim Investigational Site
city: Prague 5
country: Czechia
facility: 1160.26.0811 Boehringer Ingelheim Investigational Site
city: Praha 6
country: Czechia
facility: 1160.26.0812 Boehringer Ingelheim Investigational Site
city: Pribram
country: Czechia
facility: 1160.26.0817 Boehringer Ingelheim Investigational Site
city: Usti nad Orlici
country: Czechia
facility: 1160.26.0819 Boehringer Ingelheim Investigational Site
city: Aalborg
country: Denmark
facility: 1160.26.0837 Boehringer Ingelheim Investigational Site
city: Aarhus C
country: Denmark
facility: 1160.26.0835 Boehringer Ingelheim Investigational Site
city: Frederikssund
country: Denmark
facility: 1160.26.0838 Boehringer Ingelheim Investigational Site
city: Helsingør
country: Denmark
facility: 1160.26.0833 Boehringer Ingelheim Investigational Site
city: Herlev
country: Denmark
facility: 1160.26.0834 Boehringer Ingelheim Investigational Site
city: Horsens
country: Denmark
facility: 1160.26.0841 Boehringer Ingelheim Investigational Site
city: Hvidovre
country: Denmark
facility: 1160.26.0832 Boehringer Ingelheim Investigational Site
city: Køge
country: Denmark
facility: 1160.26.0840 Boehringer Ingelheim Investigational Site
city: Odense
country: Denmark
facility: 1160.26.0831 Boehringer Ingelheim Investigational Site
city: Roskilde
country: Denmark
facility: 1160.26.0839 Boehringer Ingelheim Investigational Site
city: Svendborg
country: Denmark
facility: 1160.26.0836 Boehringer Ingelheim Investigational Site
city: Espoo
country: Finland
facility: 1160.26.0856 Boehringer Ingelheim Investigational Site
city: HUS
country: Finland
facility: 1160.26.0851 Boehringer Ingelheim Investigational Site
city: Jyväskylä
country: Finland
facility: 1160.26.0859 Boehringer Ingelheim Investigational Site
city: Kuopio
country: Finland
facility: 1160.26.0855 Boehringer Ingelheim Investigational Site
city: Lappeenranta
country: Finland
facility: 1160.26.0857 Boehringer Ingelheim Investigational Site
city: OYS
country: Finland
facility: 1160.26.0854 Boehringer Ingelheim Investigational Site
city: Pori
country: Finland
facility: 1160.26.0858 Boehringer Ingelheim Investigational Site
city: Tampere
country: Finland
facility: 1160.26.0852 Boehringer Ingelheim Investigational Site
city: Turku
country: Finland
facility: 1160.26.0853 Boehringer Ingelheim Investigational Site
city: ABBEVILLE cedex
country: France
facility: 1160.26.0875A Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0882A Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0882B Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0882C Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0882D Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0882E Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0882G Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0882H Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0882I Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0882K Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0882L Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1160.26.0884A Boehringer Ingelheim Investigational Site
city: Cholet
country: France
facility: 1160.26.0887A Boehringer Ingelheim Investigational Site
city: Gap
country: France
facility: 1160.26.0889A Boehringer Ingelheim Investigational Site
city: Grenoble
country: France
facility: 1160.26.0888A Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0879A Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0879B Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0879C Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0879E Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0879F Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0879G Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0879H Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0879S Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0880A Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0880F Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0880G Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0880J Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0881A Boehringer Ingelheim Investigational Site
city: Joue les Tours
country: France
facility: 1160.26.0881D Boehringer Ingelheim Investigational Site
city: Joué les Tours
country: France
facility: 1160.26.0880B Boehringer Ingelheim Investigational Site
city: Joué les Tours
country: France
facility: 1160.26.0880C Boehringer Ingelheim Investigational Site
city: Joué les Tours
country: France
facility: 1160.26.0880D Boehringer Ingelheim Investigational Site
city: Joué les Tours
country: France
facility: 1160.26.0880E Boehringer Ingelheim Investigational Site
city: Langres
country: France
facility: 1160.26.0874A Boehringer Ingelheim Investigational Site
city: Langres
country: France
facility: 1160.26.0874B Boehringer Ingelheim Investigational Site
city: Paris
country: France
facility: 1160.26.0871A Boehringer Ingelheim Investigational Site
city: TOULOUSE cedex
country: France
facility: 1160.26.0873A Boehringer Ingelheim Investigational Site
city: Tourcoing
country: France
facility: 1160.26.0886A Boehringer Ingelheim Investigational Site
city: VALENCIENNES cedex
country: France
facility: 1160.26.0872A Boehringer Ingelheim Investigational Site
city: Valenciennes cedex
country: France
facility: 1160.26.0872C Boehringer Ingelheim Investigational Site
city: Valenciennes
country: France
facility: 1160.26.0872B Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 1160.26.0932 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 1160.26.0948 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 1160.26.0962 Boehringer Ingelheim Investigational Site
city: Bochum
country: Germany
facility: 1160.26.0940 Boehringer Ingelheim Investigational Site
city: Coburg
country: Germany
facility: 1160.26.0936 Boehringer Ingelheim Investigational Site
city: Dachau
country: Germany
facility: 1160.26.0968 Boehringer Ingelheim Investigational Site
city: Dortmund
country: Germany
facility: 1160.26.0972 Boehringer Ingelheim Investigational Site
city: Duisburg
country: Germany
facility: 1160.26.0957 Boehringer Ingelheim Investigational Site
city: Erlangen
country: Germany
facility: 1160.26.0971 Boehringer Ingelheim Investigational Site
city: Eschweiler
country: Germany
facility: 1160.26.0965 Boehringer Ingelheim Investigational Site
city: Essen
country: Germany
facility: 1160.26.0934 Boehringer Ingelheim Investigational Site
city: Frankfurt/Main
country: Germany
facility: 1160.26.0931 Boehringer Ingelheim Investigational Site
city: Heidelberg
country: Germany
facility: 1160.26.0943 Boehringer Ingelheim Investigational Site
city: Kassel
country: Germany
facility: 1160.26.0955 Boehringer Ingelheim Investigational Site
city: Köln
country: Germany
facility: 1160.26.0963 Boehringer Ingelheim Investigational Site
city: Lahr
country: Germany
facility: 1160.26.0946 Boehringer Ingelheim Investigational Site
city: Limburg
country: Germany
facility: 1160.26.0944 Boehringer Ingelheim Investigational Site
city: Mainz
country: Germany
facility: 1160.26.0951 Boehringer Ingelheim Investigational Site
city: Mannheim
country: Germany
facility: 1160.26.0933 Boehringer Ingelheim Investigational Site
city: Mannheim
country: Germany
facility: 1160.26.0945 Boehringer Ingelheim Investigational Site
city: Mannheim
country: Germany
facility: 1160.26.0970 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 1160.26.0947 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 1160.26.0952 Boehringer Ingelheim Investigational Site
city: Papenburg
country: Germany
facility: 1160.26.0941 Boehringer Ingelheim Investigational Site
city: Suhl
country: Germany
facility: 1160.26.0959 Boehringer Ingelheim Investigational Site
city: Witten
country: Germany
facility: 1160.26.0937 Boehringer Ingelheim Investigational Site
city: Wuppertal
country: Germany
facility: 1160.26.0966 Boehringer Ingelheim Investigational Site
city: Alexandroupolis
country: Greece
facility: 1160.26.0908 University Hospital of Alexandroupolis
city: Athens
country: Greece
facility: 1160.26.0901 General Hospital "Alexandra", Therapeutic Clinic UOA
city: Athens
country: Greece
facility: 1160.26.0906 General Hospital ";Evangelismos"
city: Athens
country: Greece
facility: 1160.26.0907 "Pammakaristos" Hospital of Athens
city: Athens
country: Greece
facility: 1160.26.0915 "Hippokratio" Hospital of Athens
city: Kalamaria-Thessaloniki
country: Greece
facility: 1160.26.0914 2nd IKA Hospital, Thessaloniki
city: Larissa
country: Greece
facility: 1160.26.0904 General Hospital of Larissa
city: Larissa
country: Greece
facility: 1160.26.0913 University Hospital of Larissa
city: Leivadia
country: Greece
facility: 1160.26.0912 General Hospital of Leivadia
city: Thessaloniki
country: Greece
facility: 1160.26.0902 General Hospital " Papageorgiou"
city: Thiva
country: Greece
facility: 1160.26.0910 General Hospital of Thiva
city: Trikala
country: Greece
facility: 1160.26.0903 General Hospital of Trikala
city: Voula - Athens
country: Greece
facility: 1160.26.0905 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 1160.26.1001 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 1160.26.1002 Boehringer Ingelheim Investigational Site
city: Kowloon
country: Hong Kong
facility: 1160.26.1003 Boehringer Ingelheim Investigational Site
city: Kowloon
country: Hong Kong
facility: 1160.26.1004 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 1160.26.1011 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 1160.26.1012 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 1160.26.1013 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 1160.26.1014 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 1160.26.1015 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 1160.26.1016 Boehringer Ingelheim Investigational Site
city: Gyongyos
country: Hungary
facility: 1160.26.1020 Boehringer Ingelheim Investigational Site
city: Komarom
country: Hungary
facility: 1160.26.1017 Boehringer Ingelheim Investigational Site
city: Pecs
country: Hungary
facility: 1160.26.1018 Boehringer Ingelheim Investigational Site
city: Veszprem
country: Hungary
facility: 1160.26.1019 Boehringer Ingelheim Investigational Site
city: Ahmedabad
country: India
facility: 1160.26.1056 Boehringer Ingelheim Investigational Site
city: Ahmedabad
country: India
facility: 1160.26.1057 Boehringer Ingelheim Investigational Site
city: Bangalore
country: India
facility: 1160.26.1064 Boehringer Ingelheim Investigational Site
city: Bangalore
country: India
facility: 1160.26.1065 Boehringer Ingelheim Investigational Site
city: Bikaner
country: India
facility: 1160.26.1071 Boehringer Ingelheim Investigational Site
city: Chennai
country: India
facility: 1160.26.1066 Boehringer Ingelheim Investigational Site
city: Coimbatore
country: India
facility: 1160.26.1069 Boehringer Ingelheim Investigational Site
city: Hyderabad
country: India
facility: 1160.26.1062 Boehringer Ingelheim Investigational Site
city: Indore
country: India
facility: 1160.26.1058 Boehringer Ingelheim Investigational Site
city: Jaipur
country: India
facility: 1160.26.1053 Boehringer Ingelheim Investigational Site
city: Jaipur
country: India
facility: 1160.26.1073 Boehringer Ingelheim Investigational Site
city: Kerala
country: India
facility: 1160.26.1067 Boehringer Ingelheim Investigational Site
city: Kottayam
country: India
facility: 1160.26.1068 Boehringer Ingelheim Investigational Site
city: Lucknow
country: India
facility: 1160.26.1055 Boehringer Ingelheim Investigational Site
city: Ludhiana
country: India
facility: 1160.26.1051 Boehringer Ingelheim Investigational Site
city: Mumbai
country: India
facility: 1160.26.1060 Boehringer Ingelheim Investigational Site
city: Mysore
country: India
facility: 1160.26.1072 Boehringer Ingelheim Investigational Site
city: Nagpur
country: India
facility: 1160.26.1059 Boehringer Ingelheim Investigational Site
city: New Delhi
country: India
facility: 1160.26.1052 Boehringer Ingelheim Investigational Site
city: Pune
country: India
facility: 1160.26.1070 Boehringer Ingelheim Investigational Site
city: Afula
country: Israel
facility: 1160.26.1110 Boehringer Ingelheim Investigational Site
city: Afula
country: Israel
facility: 1160.26.1121 Boehringer Ingelheim Investigational Site
city: Ashkelon
country: Israel
facility: 1160.26.1111 Boehringer Ingelheim Investigational Site
city: Be´er Scheva
country: Israel
facility: 1160.26.1102 Boehringer Ingelheim Investigational Site
city: Givatayim
country: Israel
facility: 1160.26.1117 Boehringer Ingelheim Investigational Site
city: Hadera
country: Israel
facility: 1160.26.1112 Boehringer Ingelheim Investigational Site
city: Haifa
country: Israel
facility: 1160.26.1091 Boehringer Ingelheim Investigational Site
city: Haifa
country: Israel
facility: 1160.26.1113 Boehringer Ingelheim Investigational Site
city: Haifa
country: Israel
facility: 1160.26.1114 Boehringer Ingelheim Investigational Site
city: Haifa
country: Israel
facility: 1160.26.1116 Boehringer Ingelheim Investigational Site
city: Haifa
country: Israel
facility: 1160.26.1118 Boehringer Ingelheim Investigational Site
city: Holon
country: Israel
facility: 1160.26.1105 Boehringer Ingelheim Investigational Site
city: Jerusalem
country: Israel
facility: 1160.26.1097 Boehringer Ingelheim Investigational Site
city: Jerusalem
country: Israel
facility: 1160.26.1101 Boehringer Ingelheim Investigational Site
city: Jerusalem
country: Israel
facility: 1160.26.1104 Boehringer Ingelheim Investigational Site
city: Jerusalem
country: Israel
facility: 1160.26.1106 Boehringer Ingelheim Investigational Site
city: Kfar Saba
country: Israel
facility: 1160.26.1119 Boehringer Ingelheim Investigational Site
city: Nazareth
country: Israel
facility: 1160.26.1115 Boehringer Ingelheim Investigational Site
city: Petah Tikva
country: Israel
facility: 1160.26.1096 Boehringer Ingelheim Investigational Site
city: Ramat Gan
country: Israel
facility: 1160.26.1093 Boehringer Ingelheim Investigational Site
city: Ramat Gan
country: Israel
facility: 1160.26.1094 Boehringer Ingelheim Investigational Site
city: Ramat Gan
country: Israel
facility: 1160.26.1095 Boehringer Ingelheim Investigational Site
city: Rehovot
country: Israel
facility: 1160.26.1100 Boehringer Ingelheim Investigational Site
city: Safed
country: Israel
facility: 1160.26.1103 Boehringer Ingelheim Investigational Site
city: Tel Hashomer
country: Israel
facility: 1160.26.1092 Boehringer Ingelheim Investigational Site
city: Tel Hashomer
country: Israel
facility: 1160.26.1098 Boehringer Ingelheim Investigational Site
city: Tel-Aviv
country: Israel
facility: 1160.26.1107 Boehringer Ingelheim Investigational Site
city: Tel-Aviv
country: Israel
facility: 1160.26.1108 Boehringer Ingelheim Investigational Site
city: Tel-Aviv
country: Israel
facility: 1160.26.1109 Boehringer Ingelheim Investigational Site
city: Tel-Aviv
country: Israel
facility: 1160.26.1120 Boehringer Ingelheim Investigational Site
city: Tel-Aviv
country: Israel
facility: 1160.26.1122 Boehringer Ingelheim Investigational Site
city: Zerifin
country: Israel
facility: 1160.26.1099 Boehringer Ingelheim Investigational Site
city: Arezzo
country: Italy
facility: 1160.26.1169 Boehringer Ingelheim Investigational Site
city: Ascoli Piceno
country: Italy
facility: 1160.26.1172 Boehringer Ingelheim Investigational Site
city: Bentivoglio (BO)
country: Italy
facility: 1160.26.1180 Boehringer Ingelheim Investigational Site
city: Bologna
country: Italy
facility: 1160.26.1161 Boehringer Ingelheim Investigational Site
city: Castelnuovo Garfagnana
country: Italy
facility: 1160.26.1163 Boehringer Ingelheim Investigational Site
city: Chieti
country: Italy
facility: 1160.26.1178 Boehringer Ingelheim Investigational Site
city: Colleferro
country: Italy
facility: 1160.26.1171 Boehringer Ingelheim Investigational Site
city: Cremona
country: Italy
facility: 1160.26.1174 Boehringer Ingelheim Investigational Site
city: Eboli
country: Italy
facility: 1160.26.1167 Boehringer Ingelheim Investigational Site
city: Isernia
country: Italy
facility: 1160.26.1168 Boehringer Ingelheim Investigational Site
city: Legnago
country: Italy
facility: 1160.26.1162 Boehringer Ingelheim Investigational Site
city: Mantova
country: Italy
facility: 1160.26.1177 Boehringer Ingelheim Investigational Site
city: Perugia SAN Sisto
country: Italy
facility: 1160.26.1165 Boehringer Ingelheim Investigational Site
city: Roma
country: Italy
facility: 1160.26.1175 Boehringer Ingelheim Investigational Site
city: San Bonifacio
country: Italy
facility: 1160.26.1181 Boehringer Ingelheim Investigational Site
city: San Daniele Del Friuli
country: Italy
facility: 1160.26.1173 Boehringer Ingelheim Investigational Site
city: Sassari
country: Italy
facility: 1160.26.1170 Boehringer Ingelheim Investigational Site
city: Sassari
country: Italy
facility: 1160.26.1176 Boehringer Ingelheim Investigational Site
city: Abeno-ku, Osaka, Osaka
country: Japan
facility: 1160.26.1204 Boehringer Ingelheim Investigational Site
city: Aki-gun, Hiroshima
country: Japan
facility: 1160.26.1209 Boehringer Ingelheim Investigational Site
city: Aoba-ku, Sendai, Miyagi
country: Japan
facility: 1160.26.1193 Boehringer Ingelheim Investigational Site
city: Chuo-ku, Fukuoka, Fukuoka
country: Japan
facility: 1160.26.1211 Boehringer Ingelheim Investigational Site
city: Chuo-ku, Fukuoka, Fukuoka
country: Japan
facility: 1160.26.1225 Boehringer Ingelheim Investigational Site
city: Chuo-ku, Kobe, Hyogo
country: Japan
facility: 1160.26.1221 Boehringer Ingelheim Investigational Site
city: Chuo-ku, Osaka, Osaka
country: Japan
facility: 1160.26.1219 Boehringer Ingelheim Investigational Site
city: Fujioka-shi , Gunma-ken
country: Japan
facility: 1160.26.1229 Boehringer Ingelheim Investigational Site
city: Fukushima-shi,Fukushima-ken
country: Japan
facility: 1160.26.1232 Boehringer Ingelheim Investigational Site
city: Higashimatsushimashi, Miyagi-ken
country: Japan
facility: 1160.26.1228 Boehringer Ingelheim Investigational Site
city: Himeji, Hyogo
country: Japan
facility: 1160.26.1208 Boehringer Ingelheim Investigational Site
city: Iida, Nagano
country: Japan
facility: 1160.26.1214 Boehringer Ingelheim Investigational Site
city: Isesaki-shi,Gunma
country: Japan
facility: 1160.26.1240 Boehringer Ingelheim Investigational Site
city: Iwakuni, Yamaguchi
country: Japan
facility: 1160.26.1224 Boehringer Ingelheim Investigational Site
city: Izumi-ku, Sendai, Miyagi
country: Japan
facility: 1160.26.1194 Boehringer Ingelheim Investigational Site
city: Kamigyo-ku, Kyoto
country: Japan
facility: 1160.26.1241 Boehringer Ingelheim Investigational Site
city: Kawachinagano, Osaka
country: Japan
facility: 1160.26.1220 Boehringer Ingelheim Investigational Site
city: Kita-ku, Osaka, Osaka
country: Japan
facility: 1160.26.1203 Boehringer Ingelheim Investigational Site
city: Kita-ku, Sakai, Osaka
country: Japan
facility: 1160.26.1207 Boehringer Ingelheim Investigational Site
city: Komatsu-shi,Ishikawa -ken
country: Japan
facility: 1160.26.1231 Boehringer Ingelheim Investigational Site
city: Kyoto-shi,Kyoto
country: Japan
facility: 1160.26.1233 Boehringer Ingelheim Investigational Site
city: Matsumoto, Nagano
country: Japan
facility: 1160.26.1242 Boehringer Ingelheim Investigational Site
city: Minami-ku, Fukuoka, Fukuoka
country: Japan
facility: 1160.26.1210 Boehringer Ingelheim Investigational Site
city: Minato, Tokyo
country: Japan
facility: 1160.26.1218 Boehringer Ingelheim Investigational Site
city: Minato-ku, Nagoya, Aichi
country: Japan
facility: 1160.26.1200 Boehringer Ingelheim Investigational Site
city: Minato-ku, Nagoya, Aichi
country: Japan
facility: 1160.26.1201 Boehringer Ingelheim Investigational Site
city: Narashino, Chiba
country: Japan
facility: 1160.26.1216 Boehringer Ingelheim Investigational Site
city: Nishinomiya-shi,Hyogo
country: Japan
facility: 1160.26.1237 Boehringer Ingelheim Investigational Site
city: Okayama, Okayama
country: Japan
facility: 1160.26.1223 Boehringer Ingelheim Investigational Site
city: Oota, Tokyo
country: Japan
facility: 1160.26.1197 Boehringer Ingelheim Investigational Site
city: Otaru, Hokkaido
country: Japan
facility: 1160.26.1212 Boehringer Ingelheim Investigational Site
city: Sagamihara, Kanagawa-ken
country: Japan
facility: 1160.26.1230 Boehringer Ingelheim Investigational Site
city: Sapporo-shi,Hokkai-do
country: Japan
facility: 1160.26.1238 Boehringer Ingelheim Investigational Site
city: Shibuya, Tokyo
country: Japan
facility: 1160.26.1217 Boehringer Ingelheim Investigational Site
city: Shinjuku, Tokyo
country: Japan
facility: 1160.26.1196 Boehringer Ingelheim Investigational Site
city: Shiroishi-ku, Sapporo, Hokkaido
country: Japan
facility: 1160.26.1191 Boehringer Ingelheim Investigational Site
city: Shiroishi-ku, Sapporo, Hokkaido
country: Japan
facility: 1160.26.1192 Boehringer Ingelheim Investigational Site
city: Suita, Osaka
country: Japan
facility: 1160.26.1206 Boehringer Ingelheim Investigational Site
city: Suita-shi, Osaka
country: Japan
facility: 1160.26.1235 Boehringer Ingelheim Investigational Site
city: Suita-shi, Osaka
country: Japan
facility: 1160.26.1236 Boehringer Ingelheim Investigational Site
city: Sumiyoshi-ku, Osaka, Osaka
country: Japan
facility: 1160.26.1205 Boehringer Ingelheim Investigational Site
city: Takatsuki-shi,Osaka
country: Japan
facility: 1160.26.1234 Boehringer Ingelheim Investigational Site
city: Tokorozawa, Saitama
country: Japan
facility: 1160.26.1215 Boehringer Ingelheim Investigational Site
city: Totsuka-ku, Yokohama, Kanagawa
country: Japan
facility: 1160.26.1198 Boehringer Ingelheim Investigational Site
city: Tsuchiura, Ibaragi
country: Japan
facility: 1160.26.1195 Boehringer Ingelheim Investigational Site
city: Ueda, Nagano
country: Japan
facility: 1160.26.1199 Boehringer Ingelheim Investigational Site
city: Wakayama, Wakayama
country: Japan
facility: 1160.26.1222 Boehringer Ingelheim Investigational Site
city: Yanagawa, Fukuoka
country: Japan
facility: 1160.26.1227 Boehringer Ingelheim Investigational Site
city: Yao, Osaka
country: Japan
facility: 1160.26.1243 Boehringer Ingelheim Investigational Site
city: Busan
country: Korea, Republic of
facility: 1160.26.1585 Boehringer Ingelheim Investigational Site
city: Chungchungnam-Do
country: Korea, Republic of
facility: 1160.26.1586 Boehringer Ingelheim Investigational Site
city: Daegu
country: Korea, Republic of
facility: 1160.26.1584 Boehringer Ingelheim Investigational Site
city: Daegu
country: Korea, Republic of
facility: 1160.26.1591 Boehringer Ingelheim Investigational Site
city: Gwangju
country: Korea, Republic of
facility: 1160.26.1590 Boehringer Ingelheim Investigational Site
city: Incheon
country: Korea, Republic of
facility: 1160.26.1581 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1160.26.1582 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1160.26.1583 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1160.26.1588 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1160.26.1589 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1160.26.1592 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1160.26.1593 Boehringer Ingelheim Investigational Site
city: Kajang,Selangor
country: Malaysia
facility: 1160.26.1297 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 1160.26.1291 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 1160.26.1292 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 1160.26.1294 Boehringer Ingelheim Investigational Site
city: Kuching
country: Malaysia
facility: 1160.26.1293 Boehringer Ingelheim Investigational Site
city: Penang
country: Malaysia
facility: 1160.26.1295 Boehringer Ingelheim Investigational Site
city: Penang
country: Malaysia
facility: 1160.26.1296 Boehringer Ingelheim Investigational Site
city: Durango
country: Mexico
facility: 1160.26.1318 Hospital General "Dr. Santiago Ramón y Cajal
city: Guadalajara
country: Mexico
facility: 1160.26.1311 Hospital Mexico-Americano
city: Guadalajara
country: Mexico
facility: 1160.26.1317 hOSPITAL bERNARDETTE
city: Mexico
country: Mexico
facility: 1160.26.1312 Hospital de Jesus
city: Mexico
country: Mexico
facility: 1160.26.1319 Instituto Nacional de Cardiologia
city: México
country: Mexico
facility: 1160.26.1314 Hospital 1o. de Octubre
city: San Luis Potosí
country: Mexico
facility: 1160.26.1313 Hosp. Angeles Centro Medico del Potosi
city: San Luis Potosí
country: Mexico
facility: 1160.26.1322 Hospital Central "Dr. Ignacio Morones Prieto"
city: Almelo
country: Netherlands
facility: 1160.26.1344 Boehringer Ingelheim Investigational Site
city: Amsterdam
country: Netherlands
facility: 1160.26.1331 Boehringer Ingelheim Investigational Site
city: Apeldoorn
country: Netherlands
facility: 1160.26.1336 Boehringer Ingelheim Investigational Site
city: Breda
country: Netherlands
facility: 1160.26.1332 Boehringer Ingelheim Investigational Site
city: Den Bosch
country: Netherlands
facility: 1160.26.1337 Boehringer Ingelheim Investigational Site
city: Den Helder
country: Netherlands
facility: 1160.26.1349 Boehringer Ingelheim Investigational Site
city: Deventer
country: Netherlands
facility: 1160.26.1345 Boehringer Ingelheim Investigational Site
city: Dirksland
country: Netherlands
facility: 1160.26.1360 Boehringer Ingelheim Investigational Site
city: Dordrecht
country: Netherlands
facility: 1160.26.1348 Boehringer Ingelheim Investigational Site
city: Ede
country: Netherlands
facility: 1160.26.1340 Boehringer Ingelheim Investigational Site
city: Eindhoven
country: Netherlands
facility: 1160.26.1358 Boehringer Ingelheim Investigational Site
city: Enschede
country: Netherlands
facility: 1160.26.1338 Boehringer Ingelheim Investigational Site
city: Goes
country: Netherlands
facility: 1160.26.1343 Boehringer Ingelheim Investigational Site
city: Gorinchem
country: Netherlands
facility: 1160.26.1347 Boehringer Ingelheim Investigational Site
city: Groningen
country: Netherlands
facility: 1160.26.1333 Boehringer Ingelheim Investigational Site
city: Groningen
country: Netherlands
facility: 1160.26.1355 Boehringer Ingelheim Investigational Site
city: Heerlen
country: Netherlands
facility: 1160.26.1361 Boehringer Ingelheim Investigational Site
city: Hengelo
country: Netherlands
facility: 1160.26.1339 Boehringer Ingelheim Investigational Site
city: Hilversum
country: Netherlands
facility: 1160.26.1346 Boehringer Ingelheim Investigational Site
city: Hoorn
country: Netherlands
facility: 1160.26.1356 Boehringer Ingelheim Investigational Site
city: Maastricht
country: Netherlands
facility: 1160.26.1359 Boehringer Ingelheim Investigational Site
city: Meppel
country: Netherlands
facility: 1160.26.1341 Boehringer Ingelheim Investigational Site
city: Rotterdam
country: Netherlands
facility: 1160.26.1354 Boehringer Ingelheim Investigational Site
city: Sneek
country: Netherlands
facility: 1160.26.1351 Boehringer Ingelheim Investigational Site
city: Spiijkenisse
country: Netherlands
facility: 1160.26.1334 Boehringer Ingelheim Investigational Site
city: Terneuzen
country: Netherlands
facility: 1160.26.1335 Boehringer Ingelheim Investigational Site
city: Tiel
country: Netherlands
facility: 1160.26.1353 Boehringer Ingelheim Investigational Site
city: Tilburg
country: Netherlands
facility: 1160.26.1352 Boehringer Ingelheim Investigational Site
city: Veldhoven
country: Netherlands
facility: 1160.26.1350 Boehringer Ingelheim Investigational Site
city: Velp
country: Netherlands
facility: 1160.26.1342 Boehringer Ingelheim Investigational Site
city: Venlo
country: Netherlands
facility: 1160.26.1357 Boehringer Ingelheim Investigational Site
city: Gjøvik
country: Norway
facility: 1160.26.1396 Boehringer Ingelheim Investigational Site
city: Moss
country: Norway
facility: 1160.26.1393 Boehringer Ingelheim Investigational Site
city: Nordbyhagen
country: Norway
facility: 1160.26.1395 Boehringer Ingelheim Investigational Site
city: Oslo
country: Norway
facility: 1160.26.1391 Boehringer Ingelheim Investigational Site
city: Oslo
country: Norway
facility: 1160.26.1392 Boehringer Ingelheim Investigational Site
city: Oslo
country: Norway
facility: 1160.26.1397 Boehringer Ingelheim Investigational Site
city: RUD
country: Norway
facility: 1160.26.1394 Boehringer Ingelheim Investigational Site
city: Bella Vista
country: Peru
facility: 1160.26.1415 Hospital Alberto Sabogal
city: Jesús María
country: Peru
facility: 1160.26.1411 Clinica San Felipe
city: San Isidro
country: Peru
facility: 1160.26.1412 Clínica Anglo Americana
city: San Martín de Porres
country: Peru
facility: 1160.26.1413 Hospital Cayetano Heredia
city: Urbanización Sto Tomas De San Borja
country: Peru
facility: 1160.26.1414 Clínica Vesalio
city: Manila
country: Philippines
facility: 1160.26.1421 Philippine General Hospital
city: Manila
country: Philippines
facility: 1160.26.1422 Manila Doctors Hospital
city: Pasig City
country: Philippines
facility: 1160.26.1424 The Medical City
city: Quezon City
country: Philippines
facility: 1160.26.1423 Philippine Heart Center
city: Quezon City
country: Philippines
facility: 1160.26.1425 St Lukes Medical Center
city: Gdynia Redlowo
country: Poland
facility: 1160.26.1437 Boehringer Ingelheim Investigational Site
city: Gdynia
country: Poland
facility: 1160.26.1436 Boehringer Ingelheim Investigational Site
city: Gdynia
country: Poland
facility: 1160.26.1438 Boehringer Ingelheim Investigational Site
city: Katowice
country: Poland
facility: 1160.26.1435 Boehringer Ingelheim Investigational Site
city: Krakow
country: Poland
facility: 1160.26.1439 Boehringer Ingelheim Investigational Site
city: Krakow
country: Poland
facility: 1160.26.1440 Boehringer Ingelheim Investigational Site
city: Pulawy
country: Poland
facility: 1160.26.1433 Boehringer Ingelheim Investigational Site
city: Warsaw
country: Poland
facility: 1160.26.1431 Boehringer Ingelheim Investigational Site
city: Warsaw
country: Poland
facility: 1160.26.1432 Boehringer Ingelheim Investigational Site
city: Zabrze
country: Poland
facility: 1160.26.1434 Boehringer Ingelheim Investigational Site
city: Amadora
country: Portugal
facility: 1160.26.1456 Boehringer Ingelheim Investigational Site
city: Carnaxide
country: Portugal
facility: 1160.26.1451 Boehringer Ingelheim Investigational Site
city: Coimbra
country: Portugal
facility: 1160.26.1454 Boehringer Ingelheim Investigational Site
city: Coimbra
country: Portugal
facility: 1160.26.1459 Boehringer Ingelheim Investigational Site
city: Covilhã
country: Portugal
facility: 1160.26.1457 Boehringer Ingelheim Investigational Site
city: Lisboa
country: Portugal
facility: 1160.26.1453 Boehringer Ingelheim Investigational Site
city: Lisboa
country: Portugal
facility: 1160.26.1458 Boehringer Ingelheim Investigational Site
city: Porto
country: Portugal
facility: 1160.26.1455 Boehringer Ingelheim Investigational Site
city: Setúbal
country: Portugal
facility: 1160.26.1452 Boehringer Ingelheim Investigational Site
city: Bucharest
country: Romania
facility: 1160.26.1471 Boehringer Ingelheim Investigational Site
city: Bucharest
country: Romania
facility: 1160.26.1472 Boehringer Ingelheim Investigational Site
city: Cluj Napoca
country: Romania
facility: 1160.26.1478 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1501 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1502 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1503 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1504 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1505 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1506 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1507 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1508 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1509 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1510 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1160.26.1511 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1160.26.1512 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1160.26.1513 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1160.26.1514 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1160.26.1515 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 1160.26.1531 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 1160.26.1532 Boehringer Ingelheim Investigational Site
city: Banska Bystrica
country: Slovakia
facility: 1160.26.1548 Boehringer Ingelheim Investigational Site
city: Bratislava
country: Slovakia
facility: 1160.26.1541 Boehringer Ingelheim Investigational Site
city: Bratislava
country: Slovakia
facility: 1160.26.1542 Boehringer Ingelheim Investigational Site
city: Bratislava
country: Slovakia
facility: 1160.26.1543 Boehringer Ingelheim Investigational Site
city: Bratislava
country: Slovakia
facility: 1160.26.1544 Boehringer Ingelheim Investigational Site
city: Bratislava
country: Slovakia
facility: 1160.26.1545 Boehringer Ingelheim Investigational Site
city: Bratislava
country: Slovakia
facility: 1160.26.1546 Boehringer Ingelheim Investigational Site
city: Kosice
country: Slovakia
facility: 1160.26.1549 Boehringer Ingelheim Investigational Site
city: Kosice
country: Slovakia
facility: 1160.26.1550 Boehringer Ingelheim Investigational Site
city: Zilina
country: Slovakia
facility: 1160.26.1547 Boehringer Ingelheim Investigational Site
city: Bloemfontein
country: South Africa
facility: 1160.26.1562 Boehringer Ingelheim Investigational Site
city: Boksburg
country: South Africa
facility: 1160.26.1569 Boehringer Ingelheim Investigational Site
city: Cape Town
country: South Africa
facility: 1160.26.1561 Boehringer Ingelheim Investigational Site
city: Johannesburg
country: South Africa
facility: 1160.26.1564 Boehringer Ingelheim Investigational Site
city: Johannesburg
country: South Africa
facility: 1160.26.1567 Boehringer Ingelheim Investigational Site
city: Johannesburg
country: South Africa
facility: 1160.26.1568 Boehringer Ingelheim Investigational Site
city: Pretoria
country: South Africa
facility: 1160.26.1566 Boehringer Ingelheim Investigational Site
city: Randburg
country: South Africa
facility: 1160.26.1563 Boehringer Ingelheim Investigational Site
city: Somerset West
country: South Africa
facility: 1160.26.1565 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 1160.26.1601 Boehringer Ingelheim Investigational Site
city: Cadiz
country: Spain
facility: 1160.26.1606 Boehringer Ingelheim Investigational Site
city: Fuenlabrada (Madrid)
country: Spain
facility: 1160.26.1607 Boehringer Ingelheim Investigational Site
city: Leganés, Madrid
country: Spain
facility: 1160.26.1604 Boehringer Ingelheim Investigational Site
city: Madrid-San Lorenzo Del Escorial
country: Spain
facility: 1160.26.1609 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 1160.26.1603 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 1160.26.1608 Boehringer Ingelheim Investigational Site
city: Móstoles (Madrid)
country: Spain
facility: 1160.26.1605 Boehringer Ingelheim Investigational Site
city: Sabadell
country: Spain
facility: 1160.26.1602 Boehringer Ingelheim Investigational Site
city: Göteboerg
country: Sweden
facility: 1160.26.1633 Sahlgrenska Sjukhuset
city: Jönköping
country: Sweden
facility: 1160.26.1629 AVK-mott, Spec.M1, Länssjukhuset Ryhov
city: Linköping
country: Sweden
facility: 1160.26.1631 Universitetssjukhuset i Linköping
city: Malmö
country: Sweden
facility: 1160.26.1627 Hjärtmott. ING 35, Malmö Universitetssjukhus MAS
city: Norrköping
country: Sweden
facility: 1160.26.1625 Hjärtmott./Medicinkliniken, Vrinnevisjukhuset
city: Nässjö
country: Sweden
facility: 1160.26.1628 Rådhusg. 29, Lars Mörlids Läkarmottagning
city: Stockholm
country: Sweden
facility: 1160.26.1626 Hjärtkärllaboratoriet, Danderyds Sjukhus AB
city: Stockholm
country: Sweden
facility: 1160.26.1632 Capio S:t Görans Sjukhus
city: Stockholm
country: Sweden
facility: 1160.26.1634 Södersjukhuset
city: Umeå
country: Sweden
facility: 1160.26.1624 Klin. forskningscentrum, Norrlands Universitetssjukhus
city: Uppsala
country: Sweden
facility: 1160.26.1621 Kardiologiska kliniken, Akademiska Sjukhuset
city: Uppsala
country: Sweden
facility: 1160.26.1635 UCR/Uppsala
city: Västerås
country: Sweden
facility: 1160.26.1622 Hjärtmottagningen, Centrallasarettet
city: Örebro
country: Sweden
facility: 1160.26.1623 Kardiologiska kliniken, Universitetssjukhuset
city: Basel
country: Switzerland
facility: 1160.26.1652 Boehringer Ingelheim Investigational Site
city: Bellinzona
country: Switzerland
facility: 1160.26.1655 Boehringer Ingelheim Investigational Site
city: Bern
country: Switzerland
facility: 1160.26.1651 Boehringer Ingelheim Investigational Site
city: Lugano
country: Switzerland
facility: 1160.26.1654 Boehringer Ingelheim Investigational Site
city: Changhua County
country: Taiwan
facility: 1160.26.1680 Boehringer Ingelheim Investigational Site
city: Hualien
country: Taiwan
facility: 1160.26.1683 Boehringer Ingelheim Investigational Site
city: Kaohsiung
country: Taiwan
facility: 1160.26.1682 Boehringer Ingelheim Investigational Site
city: Taichung
country: Taiwan
facility: 1160.26.1679 China Medical University Hospital
city: Tainan
country: Taiwan
facility: 1160.26.1681 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 1160.26.1671 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 1160.26.1672 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 1160.26.1673 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 1160.26.1674 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 1160.26.1675 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 1160.26.1676 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 1160.26.1677 Boehringer Ingelheim Investigational Site
city: Taoyuan
country: Taiwan
facility: 1160.26.1678 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 1160.26.1701 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 1160.26.1702 Boehringer Ingelheim Investigational Site
city: Chiangmai
country: Thailand
facility: 1160.26.1703 Boehringer Ingelheim Investigational Site
city: Khon Kaen
country: Thailand
facility: 1160.26.1704 Boehringer Ingelheim Investigational Site
city: Muang Nakhonratchasima
country: Thailand
facility: 1160.26.1705 Boehringer Ingelheim Investigational Site
city: Adana
country: Turkey
facility: 1160.26.1715 Boehringer Ingelheim Investigational Site
city: Ankara
country: Turkey
facility: 1160.26.1711 Boehringer Ingelheim Investigational Site
city: Ankara
country: Turkey
facility: 1160.26.1713 Gazi Universitesi Tip Fakultesi Kardiyoloji Abd
city: Izmir
country: Turkey
facility: 1160.26.1714 Dokuz Eylul Universitesi Tip Fakultesi
city: Dnyepropetrovsk
country: Ukraine
facility: 1160.26.1727 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 1160.26.1726 Boehringer Ingelheim Investigational Site
city: Kharkov
country: Ukraine
facility: 1160.26.1724 Boehringer Ingelheim Investigational Site
city: Kharkov
country: Ukraine
facility: 1160.26.1725 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 1160.26.1721 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 1160.26.1722 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 1160.26.1723 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 1160.26.1728 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 1160.26.1730 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 1160.26.1731 Boehringer Ingelheim Investigational Site
city: Lvov
country: Ukraine
facility: 1160.26.1729 Boehringer Ingelheim Investigational Site
city: Birmingham
country: United Kingdom
facility: 1160.26.1744 Boehringer Ingelheim Investigational Site
city: Chertsey
country: United Kingdom
facility: 1160.26.1746 Boehringer Ingelheim Investigational Site
city: Glasgow
country: United Kingdom
facility: 1160.26.1747 Boehringer Ingelheim Investigational Site
city: Harrow
country: United Kingdom
facility: 1160.26.1750 Boehringer Ingelheim Investigational Site
city: Hull
country: United Kingdom
facility: 1160.26.1753 Boehringer Ingelheim Investigational Site
city: Kirkcaldy, Fife
country: United Kingdom
facility: 1160.26.1755 Boehringer Ingelheim Investigational Site
city: Londonderry
country: United Kingdom
facility: 1160.26.1749 Boehringer Ingelheim Investigational Site
city: London
country: United Kingdom
facility: 1160.26.1741 Boehringer Ingelheim Investigational Site
city: London
country: United Kingdom
facility: 1160.26.1756 Boehringer Ingelheim Investigational Site
city: Newcastle upon Tyne
country: United Kingdom
facility: 1160.26.1742 Boehringer Ingelheim Investigational Site
city: Newport
country: United Kingdom
facility: 1160.26.1751 Boehringer Ingelheim Investigational Site
city: Northampton
country: United Kingdom
facility: 1160.26.1752 Boehringer Ingelheim Investigational Site
city: Portadown, County Atrim
country: United Kingdom
facility: 1160.26.1745 Boehringer Ingelheim Investigational Site
city: Romford, Essex
country: United Kingdom
facility: 1160.26.1743 Boehringer Ingelheim Investigational Site
city: Stoke-On-Trent
country: United Kingdom
facility: 1160.26.1754 Boehringer Ingelheim Investigational Site
city: York
country: United Kingdom
facility: 1160.26.1748 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
citation: Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLoS One. 2021 Aug 19;16(8):e0256338. doi: 10.1371/journal.pone.0256338. eCollection 2021.
citation: Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262.
citation: Millenaar D, Schumacher H, Brueckmann M, Eikelboom JW, Ezekowitz M, Slawik J, Ewen S, Ukena C, Wallentin L, Connolly S, Yusuf S, Bohm M. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Am J Cardiol. 2021 Jun 15;149:27-35. doi: 10.1016/j.amjcard.2021.03.024. Epub 2021 Mar 20.
citation: Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471.
citation: Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9.
citation: Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697.
citation: Bohm M, Brueckmann M, Eikelboom JW, Ezekowitz M, Frassdorf M, Hijazi Z, Hohnloser SH, Mahfoud F, Schmieder RE, Schumacher H, Wallentin L, Yusuf S. Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. Eur Heart J. 2020 Aug 7;41(30):2848-2859. doi: 10.1093/eurheartj/ehaa247.
citation: Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation. 2019 Jun 18;139(25):2846-2856. doi: 10.1161/CIRCULATIONAHA.118.035266. Epub 2019 May 3.
citation: Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, Mazzotta G, Angeli F, Eikelboom JW, Ezekowitz MD, Connolly SJ, Yusuf S, Wallentin L. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial. J Am Heart Assoc. 2019 Jan 22;8(2):e010107. doi: 10.1161/JAHA.118.010107.
citation: Kent AP, Brueckmann M, Fraessdorf M, Connolly SJ, Yusuf S, Eikelboom JW, Oldgren J, Reilly PA, Wallentin L, Ezekowitz MD. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jul 17;72(3):255-267. doi: 10.1016/j.jacc.2018.04.063. Epub 2018 Jul 9.
citation: Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. Am Heart J. 2018 Apr;198:169-177. doi: 10.1016/j.ahj.2017.10.015. Epub 2018 Jan 5. No abstract available.
citation: Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.
citation: Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 2018 Feb 1;20(2):253-262. doi: 10.1093/europace/eux022.
citation: Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, Oldgren J, Nakamya J, Wang J, Connolly SJ. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017 Jul;103(13):1015-1023. doi: 10.1136/heartjnl-2016-310358. Epub 2017 Feb 17.
citation: Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697-1707. doi: 10.1161/CIRCULATIONAHA.116.022802. Epub 2016 Aug 28.
citation: Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation. 2016 Aug 23;134(8):589-98. doi: 10.1161/CIRCULATIONAHA.115.020950. Epub 2016 Aug 5.
citation: Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4.
citation: Siegbahn A, Oldgren J, Andersson U, Ezekowitz MD, Reilly PA, Connolly SJ, Yusuf S, Wallentin L, Eikelboom JW. D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb Haemost. 2016 May 2;115(5):921-30. doi: 10.1160/TH15-07-0529. Epub 2016 Jan 28.
citation: Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, Huber K, Reilly PA, Wallentin L, Oldgren J. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J. 2015 Dec;170(6):1151-60. doi: 10.1016/j.ahj.2015.09.018. Epub 2015 Oct 3.
citation: Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. 2015 Oct 1;196:127-31. doi: 10.1016/j.ijcard.2015.05.141. Epub 2015 May 28.
citation: Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015 Jun 16;65(23):2481-93. doi: 10.1016/j.jacc.2015.03.577.
citation: Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart. 2014 Aug;100(15):1193-200. doi: 10.1136/heartjnl-2013-304872. Epub 2014 May 2.
citation: Verdecchia P, Reboldi G, Di Pasquale G, Mazzotta G, Ambrosio G, Yang S, Pogue J, Wallentin L, Ezekowitz MD, Connolly SJ, Yusuf S; RE-LY Study Investigators. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol. 2014 Feb 15;113(4):669-75. doi: 10.1016/j.amjcard.2013.10.045. Epub 2013 Nov 23.
citation: Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014 Mar 4;129(9):961-70. doi: 10.1161/CIRCULATIONAHA.113.003628. Epub 2013 Dec 9.
citation: Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013 Nov 19;128(21):2325-32. doi: 10.1161/CIRCULATIONAHA.113.002332. Epub 2013 Sep 30.
citation: Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104. Epub 2013 Sep 27.
citation: Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S; RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013 Nov 12;128(20):2192-201. doi: 10.1161/CIRCULATIONAHA.112.000491. Epub 2013 Sep 9.
citation: Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042. Epub 2013 Jun 13.
citation: Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013 Jul;44(7):1891-6. doi: 10.1161/STROKEAHA.113.000990. Epub 2013 Jun 6.
citation: Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIRCULATIONAHA.112.001233. Epub 2013 Mar 6.
citation: Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.
citation: Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, Aisenberg J. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013 Mar;11(3):246-52.e1-5. doi: 10.1016/j.cgh.2012.10.021. Epub 2012 Oct 24.
citation: Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012 Nov 6;126(19):2309-16. doi: 10.1161/CIRCULATIONAHA.112.101808. Epub 2012 Oct 1.
citation: Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14.
citation: Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012 Apr 3;125(13):1605-16. doi: 10.1161/CIRCULATIONAHA.111.038729. Epub 2012 Feb 28.
citation: Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012 Feb 7;125(5):669-76. doi: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3.
citation: Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.
citation: Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.
citation: Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011 Jan 18;123(2):131-6. doi: 10.1161/CIRCULATIONAHA.110.977546. Epub 2011 Jan 3.
citation: Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010 Nov 30;122(22):2246-53. doi: 10.1161/CIRCULATIONAHA.110.973735.
citation: Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010 Dec;9(12):1157-1163. doi: 10.1016/S1474-4422(10)70274-X. Epub 2010 Nov 6.
citation: Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010 Sep 18;376(9745):975-83. doi: 10.1016/S0140-6736(10)61194-4.
citation: Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
citation: Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805-10, 810.e1-2. doi: 10.1016/j.ahj.2009.02.005.